{"entity":{"id":"2022","kind":"year","name":"2022 in oncology","aka":["2022"],"tldr":"Everything OnCo dates to 2022: 665 entries, 158 papers, 134 papers listed on people's pages, 124 landmarks and 98 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"665 dated entries in OnCo fall in 2022: 158 papers, 134 papers listed on people's pages, 124 landmarks, 98 trials reported, 66 approvals, 40 regulatory events, 24 financing rounds, 8 guideline changes, 4 laws and regulations, 4 technologies, 2 companies founded, 2 journals founded and 1 expected date.\n\nOf those, 25 to the day, 24 to the month and 616 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2021","2023"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2022,"events":[{"group":"approval","date":"2022","precision":"year","title":"Adagrasib approved in US","note":"KRAS G12C NSCLC (accelerated)","from":"adagrasib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Amivantamab approved in England (NICE)","note":"Locally advanced or metastatic non-small-cell lung cancer with an EGFR exon 20 insertion after platinum-based chemotherapy: not recommended.","from":"amivantamab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Axicabtagene ciloleucel approved in US","note":"Second-line LBCL refractory or relapsed within 12 months","from":"axicabtagene-ciloleucel","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Cadonilimab approved in China","note":"Recurrent/metastatic cervical cancer after platinum","from":"cadonilimab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Capmatinib & tepotinib approved in EU","note":"Tepmetko 2022; Tabrecta 2022","from":"capmatinib-tepotinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"CERVAVAC (quadrivalent HPV vaccine, India) approved in IN","note":"Prevention of HPV 6/11/16/18-related cancers and genital warts, ages 9-26. Market authorisation from the DCGI in 2022; introduced 2023","from":"cervavac","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Ciltacabtagene autoleucel approved in US","note":"Relapsed/refractory myeloma ≥4 lines","from":"ciltacabtagene-autoleucel","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Cobimetinib approved in US","note":"Histiocytic neoplasms","from":"cobimetinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Crizotinib approved in US","note":"ALK-positive inflammatory myofibroblastic tumour","from":"crizotinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Dabrafenib + trametinib approved in US","note":"BRAF V600E solid tumours, tumour-agnostic (age ≥6)","from":"dabrafenib-trametinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Darolutamide approved in US","note":"mHSPC with docetaxel (ARASENS)","from":"darolutamide","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Donafenib approved in China","note":"Radioiodine-refractory differentiated thyroid cancer","from":"donafenib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Durvalumab approved in England (NICE)","note":"Locally advanced unresectable non-small-cell lung cancer with PD-L1 on 1 percent or more of cells that has not progressed after concurrent platinum-based chemoradiation.","from":"durvalumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Durvalumab approved in US","note":"Locally advanced or metastatic biliary tract cancer (gallbladder cancer included) with gemcitabine and cisplatin (TOPAZ-1).","from":"durvalumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Eflapegrastim approved in US","note":"To decrease the incidence of febrile neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy","from":"eflapegrastim","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Enfortumab vedotin approved in EU","note":"mUC after platinum + PD-1; 1L with pembrolizumab 2024","from":"enfortumab-vedotin","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Furmonertinib approved in China","note":"First-line EGFR exon 19 deletion or L858R NSCLC (FURLONG)","from":"furmonertinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Futibatinib approved in US","note":"Previously treated FGFR2-fusion/rearranged intrahepatic cholangiocarcinoma (accelerated)","from":"futibatinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH) approved in US","note":"PATHWAY 4B5 as companion diagnostic for trastuzumab deruxtecan in HER2-low breast cancer","from":"her2-testing-assays","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Ibrutinib approved in EU","note":"Fixed-duration ibrutinib + venetoclax, first-line CLL (GLOW, CAPTIVATE)","from":"ibrutinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Ivosidenib approved in US","note":"Newly diagnosed IDH1-mutated AML with azacitidine (AGILE)","from":"ivosidenib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Linperlisib approved in CN","note":"Relapsed or refractory follicular lymphoma after two or more lines, conditional","from":"linperlisib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Lisocabtagene maraleucel approved in US","note":"Second-line LBCL (TRANSFORM)","from":"lisocabtagene-maraleucel","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Locametz (kit for Ga-68 gozetotide) approved in EU","note":"PSMA PET in prostate cancer","from":"locametz","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Locametz (kit for Ga-68 gozetotide) approved in US","note":"PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy","from":"locametz","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Loncastuximab tesirine approved in EU","note":"R/R DLBCL ≥2 lines (conditional)","from":"zynlonta","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Lutetium-177 vipivotide tetraxetan approved in EU","note":"mCRPC post-ARPI and taxane; pre-chemo 2025","from":"pluvicto","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Lutetium-177 vipivotide tetraxetan approved in US","note":"PSMA+ mCRPC after ARPI and taxane","from":"pluvicto","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Mirvetuximab soravtansine approved in US","note":"FRα-high platinum-resistant ovarian cancer (full approval 2024)","from":"mirvetuximab-soravtansine","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Mosunetuzumab approved in US","note":"R/R follicular lymphoma after ≥2 lines (accelerated)","from":"mosunetuzumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Nadofaragene firadenovec approved in US","note":"BCG-unresponsive high-risk NMIBC with CIS ± papillary tumours","from":"nadofaragene-firadenovec","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Nonavalent HPV vaccine approved in WHO","note":"Single-dose schedule recommended for girls 9-20","from":"gardasil-9","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Olaparib approved in EU","note":"Adjuvant treatment, alone or with endocrine therapy, of germline BRCA1/2-mutated HER2-negative high-risk early breast cancer after neoadjuvant or adjuvant chemotherapy (OlympiA).","from":"olaparib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Olaparib approved in US","note":"Adjuvant gBRCA high-risk HER2- early breast cancer","from":"olaparib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Olutasidenib approved in US","note":"Relapsed/refractory IDH1-mutated AML","from":"olutasidenib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Pacritinib approved in US","note":"Intermediate/high-risk myelofibrosis with platelets <50×10⁹/L","from":"pacritinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Pafolacianine approved in US","note":"Intraoperative identification of lung lesions","from":"pafolacianine","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Pembrolizumab approved in England (NICE)","note":"Untreated metastatic squamous non-small-cell lung cancer, with carboplatin and paclitaxel. TA770, published 9 February 2022, for a tumour proportion score of 0 to 49 percent, or 50...","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Pembrolizumab approved in EU","note":"Locally advanced or early-stage TNBC at high risk of recurrence: neoadjuvant with chemotherapy, then adjuvant monotherapy (KEYNOTE-522).","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Pembrolizumab approved in UK","note":"Untreated triple-negative locally recurrent unresectable or metastatic breast cancer with paclitaxel or nab-paclitaxel; NICE TA801 (29 June 2022) recommends it only for tumours wit...","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Pembrolizumab approved in UK","note":"Neoadjuvant with chemotherapy then adjuvant alone for triple-negative early breast cancer at high risk of recurrence or locally advanced disease; NICE TA851 (14 December 2022) reco...","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Pralsetinib approved in England (NICE)","note":"RET fusion-positive advanced non-small-cell lung cancer in patients who have not had a RET inhibitor: not recommended.","from":"pralsetinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Pucotenlimab approved in CN","note":"Previously treated MSI-high or dMMR advanced solid tumours; unresectable or metastatic melanoma after prior therapy","from":"pucotenlimab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Relatlimab + nivolumab approved in EU","note":"Melanoma, PD-L1 <1% restriction","from":"relatlimab-nivolumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Relatlimab + nivolumab approved in US","note":"Unresectable or metastatic melanoma, age ≥12","from":"relatlimab-nivolumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Relmacabtagene autoleucel approved in China","note":"Relapsed or refractory follicular lymphoma after two or more lines","from":"relmacabtagene-autoleucel","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Resolution ctDx FIRST approved in US","note":"Companion diagnostic for adagrasib in KRAS G12C-mutant NSCLC (plasma)","from":"resolution-ctdx-first","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Rezvilutamide approved in CN","note":"High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy","from":"rezvilutamide","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Sacituzumab govitecan approved in UK","note":"Unresectable triple-negative locally advanced or metastatic breast cancer after two or more systemic therapies, at least one for advanced disease; NICE TA819 (17 August 2022) recom...","from":"sacituzumab-govitecan","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Selpercatinib approved in US","note":"RET-fusion solid tumours (tumour-agnostic)","from":"selpercatinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Serplulimab approved in China","note":"First-line ES-SCLC with chemotherapy","from":"serplulimab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Sintilimab approved in China","note":"First-line oesophageal squamous cell carcinoma with chemotherapy (ORIENT-15)","from":"sintilimab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Sodium thiosulfate (otoprotectant) approved in US","note":"Reduce risk of ototoxicity from cisplatin in patients ≥1 month with localised, non-metastatic solid tumours","from":"sodium-thiosulfate","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Sotorasib approved in England (NICE)","note":"KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer that has progressed on, or after intolerance of, platinum-based chemotherapy or PD-1/PD-L1 imm...","from":"sotorasib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Sotorasib approved in EU","note":"EU brand Lumykras. Conditional marketing authorisation","from":"sotorasib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Sugemalimab approved in China","note":"Unresectable stage III NSCLC without progression after chemoradiotherapy (GEMSTONE-301)","from":"sugemalimab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Tabelecleucel approved in EU","note":"Relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after at least one prior therapy","from":"tabelecleucel","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Tebentafusp approved in US","note":"HLA-A*02:01+ metastatic uveal melanoma","from":"tebentafusp","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Teclistamab approved in EU","note":"R/R myeloma ≥3 lines (conditional, Aug 2022). Conditional marketing authorisation","from":"teclistamab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Teclistamab approved in US","note":"Relapsed/refractory myeloma after ≥4 lines","from":"teclistamab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Tepotinib approved in England (NICE)","note":"Advanced non-small-cell lung cancer with MET exon 14 skipping alterations. TA789, published 18 May 2022, subject to the commercial arrangement (VISION).","from":"tepotinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Tepotinib approved in EU","note":"Advanced NSCLC with MET exon 14 skipping alterations after immunotherapy or platinum chemotherapy","from":"tepotinib","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Tisagenlecleucel approved in US","note":"Relapsed/refractory follicular lymphoma","from":"tisagenlecleucel","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Trastuzumab deruxtecan approved in US","note":"HER2-low metastatic breast cancer; HER2-mutant NSCLC","from":"trastuzumab-deruxtecan","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"Tremelimumab approved in US","note":"Metastatic NSCLC without EGFR/ALK, with durvalumab and platinum chemotherapy; unresectable HCC with durvalumab","from":"tremelimumab","refs":[]},{"group":"approval","date":"2022","precision":"year","title":"TruSight Oncology Comprehensive approved in EU","note":"CE-IVD comprehensive genomic profiling","from":"trusight-oncology-comprehensive","refs":[]},{"group":"company","date":"2022","precision":"year","title":"THERYQ founded","note":"Paris","from":"theryq","refs":[]},{"group":"company","date":"2022","precision":"year","title":"Trial Library founded","note":"San Francisco, CA","from":"trial-library","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Acrivon Therapeutics: IPO","note":"IPO closed 17 November 2022 with a concurrent 5 million US dollar private placement to Chione; gross IPO proceeds not stated in the fetched filing","from":"acrivon-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Ambagon Therapeutics: Form D offering","note":"$45m. Total sold of an 85 million US dollar offering per amended Form D filed June 2022","from":"ambagon-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Arcellx: IPO","note":"$142m. 9,487,500 shares at $15.00 including full option exercise; Nasdaq ACLX","from":"arcellx","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Capstan Therapeutics: Form D offering","note":"$76m. Amount sold of a $102 million offering, first sale 14 June 2022 (filed March 2024)","from":"capstan-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Dantari: Series A","note":"$47m","from":"dantari","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Elypta: Series A","note":"$21m. Led by Bonnier Ventures, June 2022.","from":"elypta","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Enlaza Therapeutics: Seed","note":"$61m. Led by Avalon Ventures","from":"enlaza-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Geneos Therapeutics: Series A","note":"$17m. Series A2, led by Flerie Invest","from":"geneos-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Indapta Therapeutics: Form D offering","note":"$34m. Amount sold at filing of a $67 million offering, first sale 28 January 2022","from":"indapta-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Kelonia Therapeutics: Form D offering","note":"$50m. Equity offering, first sale 14 April 2022; issuer then based in Cambridge, MA","from":"kelonia-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Mablink Bioscience: Series A","note":"July 2022, led by Sofinnova Partners and Mérieux Equity Partners; amount not stated in the fetched release copy","from":"mablink-bioscience","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Microbiotica: Series B","note":"GBP 50 million; GBP 62 million equity raised to date per company","from":"microbiotica","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Naveris: Series A","note":"$51m. $33.4 million Series A expansion bringing the round to $51 million; led by Gurnet Point Capital with TechU Ventures and BrightEdge, September 2022.","from":"naveris","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Nested Therapeutics: Series A","note":"$90m. Led by Goldman Sachs Asset Management; brought total financing to 125 million US dollars since Versant Ventures founded the company","from":"nested-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Nimbus Therapeutics: Crossover","note":"$125m. Described by BioPharma Dive as a private funding round; no series letter given","from":"nimbus-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Photys Therapeutics: Series A","note":"$75m. Led by MPM Capital; company founded by Longwood Fund and Amit Choudhary of Brigham and Women's Hospital and the Broad Institute","from":"photys-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Reimagine Care: Series A","note":"$25m. Co-led by Santé Ventures, Martin Ventures and LRVHealth","from":"reimagine-care","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"SonALAsense: Series B","note":"Series B completion announced June 2022; amount not disclosed","from":"sonalasense","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Strand Therapeutics: Series A","note":"$45m. Series A1 extension","from":"strand-therapeutics","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Therapixel: Series B","note":"EUR 15 million, co-led by Crédit Mutuel Innovation and CapHorn, May 2022; over EUR 20 million raised since founding.","from":"therapixel","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Treeline Biosciences: Form D offering","note":"$261m. Total sold per Form D filed October 2022","from":"treeline-biosciences","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Trial Library: Seed","note":"$5m. March 2022, led by Lux Capital, per company About page","from":"trial-library","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Triana Biomedicines: Series A","note":"$110m. Launch announcement of 110 million US dollars total funding (seed from RA Capital and Atlas Venture plus Series A co-led by Lightspeed); the Series A portion alone is not it...","from":"triana-biomedicines","refs":[]},{"group":"funding","date":"2022","precision":"year","title":"Vergent Bioscience: Form D offering","note":"$22m. Equity offering of USD 22.09 million, first sale 17 August 2022, USD 21.54 million sold at filing","from":"vergent-bioscience","refs":[]},{"group":"history","date":"2022","precision":"year","title":"A blood test changes treatment","note":"Colorectal cancer. DYNAMIC cut adjuvant chemotherapy use in resected stage II colon cancer from 28% to 15% with non-inferior two-year recurrence-free survival, the first randomised...","from":"colorectal","refs":["paper-dynamic-nejm-2022","paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022"]},{"group":"history","date":"2022","precision":"year","title":"AALL1231 removes prophylactic cranial irradiation for most T-ALL; bortezomib helps T-lymphoblastic lymphoma only","note":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","from":"all-paediatric-high-risk","refs":["prophylactic-cranial-irradiation","bortezomib"]},{"group":"history","date":"2022","precision":"year","title":"AAML1031: sorafenib improves event-free survival in high allelic ratio FLT3-ITD AML; bortezomib adds nothing","note":"Acute myeloid leukaemia in children","from":"aml-paediatric","refs":["sorafenib","bortezomib"]},{"group":"history","date":"2022","precision":"year","title":"Adagrasib approved after KRYSTAL-1, with brain activity","note":"KRAS G12C-mutant non-small-cell lung cancer","from":"kras-g12c-nsclc","refs":["adagrasib","pasi-janne"]},{"group":"history","date":"2022","precision":"year","title":"African ancestry linked to the TNBC immune landscape","note":"Triple-negative breast cancer (TNBC). Martini's RNA sequencing of African American, West and East African tumours finds 613 ancestry-associated genes and distinct tumour-associated...","from":"tnbc","refs":["paper-martini-african-ancestry-tnbc-cancer-discov-2022","paper-huo-tcga-ancestry-breast-jama-oncol-2017"]},{"group":"history","date":"2022","precision":"year","title":"AGILE: ivosidenib plus azacitidine for unfit IDH1-mutated patients","note":"Acute myeloid leukaemia in older or unfit patients","from":"aml-older-unfit","refs":["agile","ivosidenib"]},{"group":"history","date":"2022","precision":"year","title":"AGILE: ivosidenib plus azacitidine lengthens life in newly diagnosed unfit patients; olutasidenib approved","note":"IDH1- and IDH2-mutated acute myeloid leukaemia","from":"aml-idh","refs":["agile","ivosidenib","olutasidenib"]},{"group":"history","date":"2022","precision":"year","title":"AHOD2131 opens: brentuximab vedotin and nivolumab in early-stage high-risk disease from age 5","note":"Early-stage classical Hodgkin lymphoma (stage I to II)","from":"early-stage-classical-hodgkin-lymphoma","refs":["ahod2131","brentuximab-vedotin","nivolumab"]},{"group":"history","date":"2022","precision":"year","title":"ALLIANCE A021501: adding stereotactic radiotherapy to neoadjuvant FOLFIRINOX gives worse outcomes","note":"Borderline resectable pancreatic ductal adenocarcinoma","from":"borderline-resectable-pdac","refs":["sbrt","folfirinox"]},{"group":"history","date":"2022","precision":"year","title":"ALPINE: zanubrutinib beats ibrutinib head to head","note":"Relapsed or refractory chronic lymphocytic leukaemia","from":"cll-relapsed","refs":["alpine","zanubrutinib","ibrutinib"]},{"group":"history","date":"2022","precision":"year","title":"ANCHOR: treating anal HSIL in people living with HIV cuts progression to anal cancer by 57 percent","note":"Anal high-grade squamous intraepithelial lesions (precursor)","from":"anal-hsil-precursor","refs":["precancer-ablation"]},{"group":"history","date":"2022","precision":"year","title":"ANCHOR: treating HSIL prevents anal cancer in people with HIV","note":"Anal cancer (squamous cell carcinoma)","from":"anal","refs":["precancer-ablation"]},{"group":"history","date":"2022","precision":"year","title":"ARASENS: darolutamide triplet cuts death by a third","note":"Metastatic hormone-sensitive prostate cancer","from":"prostate-mhspc","refs":["arasens","darolutamide"]},{"group":"history","date":"2022","precision":"year","title":"ASTRUM-005: serplulimab plus chemotherapy in China","note":"Extensive-stage small-cell lung cancer","from":"extensive-stage-sclc","refs":["astrum-005","serplulimab","cheng-ying","henlius"]},{"group":"history","date":"2022","precision":"year","title":"ATHENA-MONO confirms rucaparib maintenance; later-line PARP labels narrowed after survival data","note":"Platinum-sensitive ovarian cancer","from":"platinum-sensitive-ovarian-cancer","refs":["athena-mono","rucaparib"]},{"group":"history","date":"2022","precision":"year","title":"BCLC update subdivides intermediate stage and introduces treatment stage migration","note":"Intermediate hepatocellular carcinoma (BCLC B)","from":"hcc-intermediate","refs":["bclc-staging"]},{"group":"history","date":"2022","precision":"year","title":"CAPS5: 77.8 percent of surveillance-detected cancers are stage I","note":"Pancreatic ductal adenocarcinoma. 1,461 high-risk people enrolled; across CAPS1 to 5 (1,731 people) 57.9 percent of the 19 surveillance-detected cancers were stage I, with five-yea...","from":"pancreatic","refs":["pancreatic-surveillance","paper-dbouk-caps5-stage-survival-jco-2022"]},{"group":"history","date":"2022","precision":"year","title":"CheckMate 648: nivolumab + chemotherapy and nivolumab + ipilimumab approved; RATIONALE-306 reported","note":"Oesophageal cancer","from":"esophageal","refs":["checkmate-648","rationale-306"]},{"group":"history","date":"2022","precision":"year","title":"CheckMate 648: nivolumab combinations first line","note":"Oesophageal squamous cell carcinoma","from":"oesophageal-squamous-cell-carcinoma","refs":["checkmate-648"]},{"group":"history","date":"2022","precision":"year","title":"CheckMate 816: neoadjuvant immunotherapy; tremelimumab-durvalumab (POSEIDON)","note":"Non-small-cell lung cancer","from":"nsclc","refs":["checkmate-816","tremelimumab"]},{"group":"history","date":"2022","precision":"year","title":"CheckMate 816: neoadjuvant nivolumab plus chemotherapy raises pathological complete response from 2 to 24 percent","note":"Resectable stage I to III non-small-cell lung cancer","from":"resectable-nsclc","refs":["checkmate-816","nivolumab","patrick-forde","jonathan-spicer"]},{"group":"history","date":"2022","precision":"year","title":"Cobimetinib approved for adults with histiocytic neoplasms including Langerhans cell histiocytosis","note":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","from":"lch-multisystem","refs":["cobimetinib"]},{"group":"history","date":"2022","precision":"year","title":"Cobimetinib approved for histiocytic neoplasms","note":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms. FDA approval October 2022 for adults with ECD, RDD and LCH.","from":"histiocytoses","refs":["cobimetinib"]},{"group":"history","date":"2022","precision":"year","title":"Cobimetinib approved for histiocytic neoplasms in the United States","note":"Erdheim-Chester disease","from":"erdheim-chester-disease","refs":["cobimetinib"]},{"group":"history","date":"2022","precision":"year","title":"Cobimetinib approved for histiocytic neoplasms; WHO lists Rosai-Dorfman disease among histiocytic neoplasms","note":"Rosai-Dorfman-Destombes disease","from":"rosai-dorfman-disease","refs":["cobimetinib"]},{"group":"history","date":"2022","precision":"year","title":"Crizotinib approved for ALK-positive IMT","note":"Inflammatory myofibroblastic tumour (IMT). FDA, 14 July 2022, adults and children aged 1 year and older.","from":"inflammatory-myofibroblastic-tumour","refs":["crizotinib","race-for-children-act"]},{"group":"history","date":"2022","precision":"year","title":"Dabrafenib plus trametinib approved for BRAF V600E solid tumours regardless of site","note":"KRAS wild-type pancreatic ductal adenocarcinoma","from":"kras-wild-type-pdac","refs":["dabrafenib-trametinib","braf"]},{"group":"history","date":"2022","precision":"year","title":"DESTINY-Breast04 and FDA approval","note":"HER2-low and HER2-ultralow metastatic breast cancer","from":"her2-low-metastatic-breast-cancer","refs":["destiny-breast04","trastuzumab-deruxtecan"]},{"group":"history","date":"2022","precision":"year","title":"DESTINY-Breast04 includes HER2-low triple-negative tumours","note":"Metastatic triple-negative breast cancer","from":"tnbc-metastatic","refs":["destiny-breast04","trastuzumab-deruxtecan"]},{"group":"history","date":"2022","precision":"year","title":"DESTINY-Lung01: trastuzumab deruxtecan approved, the first HER2-directed lung cancer therapy","note":"HER2-mutant non-small-cell lung cancer","from":"her2-mutant-nsclc","refs":["trastuzumab-deruxtecan","daiichi-sankyo"]},{"group":"history","date":"2022","precision":"year","title":"Detecting the lineage change without a biopsy, and measuring the disparity in the genome","note":"Prostate cancer. Cell-free DNA methylation separates neuroendocrine from castration-resistant adenocarcinoma with near-perfect discrimination in two small cohorts; a 2,069-man sing...","from":"prostate","refs":["paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022","paper-stopsack-prostate-genomes-by-race-ccr-2022"]},{"group":"history","date":"2022","precision":"year","title":"Dostarlimab alone produces complete responses in every mismatch-repair deficient rectal cancer treated","note":"Rectal cancer","from":"rectal-cancer","refs":["dostarlimab","andrea-cercek","luis-diaz"]},{"group":"history","date":"2022","precision":"year","title":"Dostarlimab: complete responses in every dMMR rectal cancer treated; PARADIGM","note":"Colorectal cancer. Organ preservation without surgery in the first Memorial Sloan Kettering cohort (Cercek, NEJM); panitumumab beat bevacizumab in left-sided RAS wild-type disease.","from":"colorectal","refs":["dostarlimab","paradigm"]},{"group":"history","date":"2022","precision":"year","title":"Durvalumab added to chemotherapy (TOPAZ-1)","note":"Biliary tract cancer (all types)","from":"biliary-tract-cancer","refs":["durvalumab"]},{"group":"history","date":"2022","precision":"year","title":"E3311: reduced-dose radiotherapy after transoral surgery","note":"HPV-positive oropharyngeal cancer","from":"hpv-positive-oropharyngeal-cancer","refs":["ecog-e3311"]},{"group":"history","date":"2022","precision":"year","title":"ECHELON-1 shows overall survival benefit; WHO reclassifies nodular lymphocyte-predominant disease","note":"Hodgkin lymphoma","from":"hodgkin-lymphoma","refs":["echelon-1"]},{"group":"history","date":"2022","precision":"year","title":"ECHELON-1 six-year update shows an overall survival advantage","note":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","from":"advanced-stage-classical-hodgkin-lymphoma","refs":["echelon-1"]},{"group":"history","date":"2022","precision":"year","title":"ELN 2022 places all FLT3-ITD AML in intermediate risk","note":"FLT3-mutated acute myeloid leukaemia","from":"aml-flt3","refs":["eln-risk"]},{"group":"history","date":"2022","precision":"year","title":"ELN 2022 risk, WHO/ICC classifications, AGILE, olutasidenib","note":"Acute myeloid leukaemia. Genetics-first classification; ivosidenib-azacitidine OS HR 0.44; second IDH1 inhibitor approved.","from":"aml","refs":["eln-risk","agile","olutasidenib"]},{"group":"history","date":"2022","precision":"year","title":"ESMO-EURACAN salivary gland guideline","note":"Salivary gland cancers","from":"salivary-gland","refs":[]},{"group":"history","date":"2022","precision":"year","title":"ESTIMABL2 and IoN: no radioactive iodine for low-risk disease","note":"Papillary thyroid cancer. Both trials found equivalent outcomes without ablation.","from":"papillary-thyroid-cancer","refs":["radioiodine-therapy"]},{"group":"history","date":"2022","precision":"year","title":"ESTIMABL2: no radioiodine for low-risk disease; ASTRA adjuvant redifferentiation negative","note":"Thyroid cancer","from":"thyroid","refs":["estimabl2","astra"]},{"group":"history","date":"2022","precision":"year","title":"Euro Ewing 2012 unifies VDC/IE; DeFi positive","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["euro-ewing-2012","defi"]},{"group":"history","date":"2022","precision":"year","title":"Euro Ewing 2012: VDC/IE superior to VIDE (Lancet)","note":"Ewing sarcoma","from":"ewing-sarcoma","refs":[]},{"group":"history","date":"2022","precision":"year","title":"First bispecific: mosunetuzumab","note":"Follicular lymphoma. Off-the-shelf CD20×CD3 with ~60% CR in third line.","from":"follicular-lymphoma","refs":["mosunetuzumab"]},{"group":"history","date":"2022","precision":"year","title":"First GD2 CAR-T responses in patients","note":"Diffuse midline glioma, H3 K27-altered (including DIPG). Majzner and colleagues (Nature) report clinical and radiographic improvement with intravenous then intracerebroventricular...","from":"dipg-dmg","refs":["glioma-car-t"]},{"group":"history","date":"2022","precision":"year","title":"FOENIX-CCA2: futibatinib approved; TOPAZ-1: durvalumab added to chemotherapy","note":"Intrahepatic cholangiocarcinoma","from":"intrahepatic-cholangiocarcinoma","refs":["foenix-cca2","futibatinib","topaz-1","durvalumab"]},{"group":"history","date":"2022","precision":"year","title":"GD2 CAR-T responses in DIPG (Stanford)","note":"Glioma & glioblastoma","from":"glioblastoma","refs":["glioma-car-t"]},{"group":"history","date":"2022","precision":"year","title":"GOG 281: trametinib doubles progression-free survival","note":"Low-grade serous ovarian cancer","from":"low-grade-serous-ovarian-cancer","refs":["trametinib"]},{"group":"history","date":"2022","precision":"year","title":"GOG-0261: carboplatin-paclitaxel non-inferior to ifosfamide-paclitaxel","note":"Uterine carcinosarcoma","from":"uterine-carcinosarcoma","refs":["carboplatin","paclitaxel"]},{"group":"history","date":"2022","precision":"year","title":"HER2-low becomes a treatment category (DESTINY-Breast04)","note":"HR-positive / HER2-negative breast cancer","from":"breast-hr-positive","refs":["destiny-breast04"]},{"group":"history","date":"2022","precision":"year","title":"HER2-low: T-DXd works in 'HER2-negative' disease","note":"Triple-negative breast cancer (TNBC). DESTINY-Breast04 includes TNBC patients with HER2-low tumours.","from":"tnbc","refs":["destiny-breast04","trastuzumab-deruxtecan"]},{"group":"history","date":"2022","precision":"year","title":"HIMALAYA: durvalumab plus tremelimumab (STRIDE) beats sorafenib","note":"Advanced hepatocellular carcinoma (BCLC C)","from":"hcc-advanced","refs":["himalaya","durvalumab","tremelimumab"]},{"group":"history","date":"2022","precision":"year","title":"HIMALAYA: STRIDE approved; BCLC update adds systemic therapy for some BCLC-B","note":"Hepatocellular carcinoma","from":"hcc","refs":["himalaya","tremelimumab"]},{"group":"history","date":"2022","precision":"year","title":"Ibrutinib-venetoclax fixed duration (EU); CLL13 and GLOW","note":"Chronic lymphocytic leukaemia. Venetoclax combinations beat chemoimmunotherapy in fit patients; ibrutinib-venetoclax approved in Europe.","from":"cll","refs":["cll13-gaia","glow","captivate"]},{"group":"history","date":"2022","precision":"year","title":"ICC and WHO redefine accelerated and blast phase thresholds","note":"Chronic myeloid leukaemia, accelerated and blast phase","from":"cml-advanced-phase","refs":[]},{"group":"history","date":"2022","precision":"year","title":"IELSG32 7-year update confirms cures","note":"Primary CNS lymphoma","from":"primary-cns-lymphoma","refs":["autologous-stem-cell-transplant"]},{"group":"history","date":"2022","precision":"year","title":"INTRIGUE: ctDNA genotype predicts ripretinib vs sunitinib benefit","note":"Gastrointestinal stromal tumour (GIST)","from":"gist","refs":["ripretinib","sunitinib"]},{"group":"history","date":"2022","precision":"year","title":"INTRIGUE: ripretinib not superior to sunitinib second line; genotype subgroups diverge","note":"Imatinib-resistant GIST","from":"gist-imatinib-resistant","refs":["nct03673501","ripretinib","sunitinib"]},{"group":"history","date":"2022","precision":"year","title":"IPSS-M adds mutations to risk scoring","note":"Lower-risk myelodysplastic syndromes","from":"mds-lower-risk","refs":[]},{"group":"history","date":"2022","precision":"year","title":"IPSS-M and WHO5/ICC","note":"Myelodysplastic syndromes / neoplasms (MDS). Molecular risk model with 31 genes; classification renamed myelodysplastic neoplasms with genetically defined entities.","from":"mds","refs":[]},{"group":"history","date":"2022","precision":"year","title":"Joint European polyp guideline updated","note":"Gallbladder cancer. ESGAR, EAES, EFISDS and ESGE set size and risk-factor rules for cholecystectomy and ultrasound follow-up.","from":"gallbladder","refs":["gallbladder-polyp","paper-gallbladder-polyp-joint-guideline-eur-radiol-2022"]},{"group":"history","date":"2022","precision":"year","title":"LMS-04: doxorubicin plus trabectedin doubles progression-free survival in leiomyosarcoma","note":"Soft tissue sarcoma of the extremity (localised and advanced)","from":"extremity-soft-tissue-sarcoma","refs":["lms-04"]},{"group":"history","date":"2022","precision":"year","title":"LMS-04: doxorubicin plus trabectedin improves progression-free survival","note":"Uterine sarcoma. Pautier and colleagues, Lancet Oncol.","from":"uterine-sarcoma","refs":["doxorubicin","trabectedin"]},{"group":"history","date":"2022","precision":"year","title":"LMS-04: doxorubicin plus trabectedin improves progression-free survival","note":"Leiomyosarcoma","from":"leiomyosarcoma","refs":["trabectedin"]},{"group":"history","date":"2022","precision":"year","title":"Mirvetuximab soravtansine accelerated approval after SORAYA","note":"Platinum-resistant ovarian cancer","from":"platinum-resistant-ovarian-cancer","refs":["mirvetuximab-soravtansine"]},{"group":"history","date":"2022","precision":"year","title":"Mirvetuximab soravtansine approved for platinum-resistant disease","note":"High-grade serous ovarian cancer","from":"high-grade-serous-ovarian-cancer","refs":["mirvetuximab-soravtansine"]},{"group":"history","date":"2022","precision":"year","title":"Mirvetuximab soravtansine: first ovarian ADC","note":"Ovarian cancer. Accelerated approval; full approval after MIRASOL OS benefit in 2024.","from":"ovarian","refs":["mirvetuximab-soravtansine","mirasol"]},{"group":"history","date":"2022","precision":"year","title":"Mirvetuximab: first ovarian ADC","note":"Ovarian cancer","from":"ovarian","refs":["mirvetuximab-soravtansine"]},{"group":"history","date":"2022","precision":"year","title":"MOCCA and other trials test immunotherapy in clear cell carcinoma","note":"Clear cell ovarian cancer","from":"clear-cell-ovarian-cancer","refs":["pembrolizumab"]},{"group":"history","date":"2022","precision":"year","title":"MOUNTAINEER: tucatinib plus trastuzumab, response rate 38 percent, median survival 24 months","note":"HER2-amplified colorectal cancer","from":"her2-amplified-colorectal","refs":["mountaineer","tucatinib","tanios-bekaii-saab"]},{"group":"history","date":"2022","precision":"year","title":"MSK-IMPACT reference cohort","note":"Gallbladder cancer. 244 samples: TP53 63%, CDKN2A 21%, ERBB2 15%, KRAS 11%, actionable alterations in 35% of patients (Giraldo et al., Clinical Cancer Research).","from":"gallbladder","refs":["paper-giraldo-gallbladder-msk-impact-ccr-2022"]},{"group":"history","date":"2022","precision":"year","title":"Nadofaragene firadenovec: first bladder gene therapy","note":"Bladder & urothelial cancer","from":"urothelial","refs":["nadofaragene-firadenovec"]},{"group":"history","date":"2022","precision":"year","title":"Nadofaragene firadenovec: first gene therapy for bladder cancer","note":"Non-muscle-invasive bladder cancer","from":"non-muscle-invasive-bladder-cancer","refs":["nadofaragene-firadenovec"]},{"group":"history","date":"2022","precision":"year","title":"NCCN publishes a dedicated ampullary adenocarcinoma guideline","note":"Ampullary cancer (ampulla of Vater). Subtype-directed treatment recommendations formalised.","from":"ampullary","refs":[]},{"group":"history","date":"2022","precision":"year","title":"Neoadjuvant cemiplimab: 51% pathological complete response (NEJM)","note":"Cutaneous squamous cell carcinoma","from":"cutaneous-scc","refs":["cemiplimab"]},{"group":"history","date":"2022","precision":"year","title":"Neoadjuvant cemiplimab: pathological complete response in 51 percent (NEJM)","note":"Advanced cutaneous squamous cell carcinoma","from":"advanced-cutaneous-scc","refs":["cemiplimab"]},{"group":"history","date":"2022","precision":"year","title":"Neurofibromatosis type 2 renamed NF2-related schwannomatosis","note":"Vestibular schwannoma (acoustic neuroma)","from":"vestibular-schwannoma","refs":[]},{"group":"history","date":"2022","precision":"year","title":"NICHE-2 neoadjuvant nivolumab-ipilimumab and dostarlimab in rectal cancer","note":"Mismatch-repair deficient (MSI-high) colorectal cancer","from":"msi-high-colorectal","refs":["niche-2","dostarlimab","andrea-cercek"]},{"group":"history","date":"2022","precision":"year","title":"Nivolumab-relatlimab (Opdualag) approved; tebentafusp approved; SWOG S1801 shows neoadjuvant benefit","note":"Melanoma","from":"melanoma","refs":["relativity-047","relatlimab-nivolumab","tebentafusp","swog-s1801"]},{"group":"history","date":"2022","precision":"year","title":"NordICC: the first randomised trial of screening colonoscopy","note":"Colorectal cancer. 84,585 people in Poland, Norway and Sweden; a single invitation cut the 10-year risk of colorectal cancer from 1.20 to 0.98 percent, with 455 invitations needed...","from":"colorectal","refs":["colorectal-screening","colonoscopy"]},{"group":"history","date":"2022","precision":"year","title":"OPRA: about half of patients keep their rectum after total neoadjuvant therapy","note":"Rectal cancer","from":"rectal-cancer","refs":["opra","julio-garcia-aguilar"]},{"group":"history","date":"2022","precision":"year","title":"PACIFIC five-year update: 42.9 percent alive versus 33.4 percent","note":"Unresectable stage III non-small-cell lung cancer","from":"stage-iii-unresectable-nsclc","refs":["pacific","durvalumab"]},{"group":"history","date":"2022","precision":"year","title":"Pacritinib approved for severe thrombocytopenia after PERSIST-2","note":"Primary myelofibrosis","from":"primary-myelofibrosis","refs":["pacritinib"]},{"group":"history","date":"2022","precision":"year","title":"Pacritinib for severe thrombocytopenia","note":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","from":"myeloproliferative-neoplasms","refs":["pacritinib"]},{"group":"history","date":"2022","precision":"year","title":"Pembrolizumab responses reported in the KEYNOTE-158 vulvar cohort","note":"HPV-associated vulvar squamous cell carcinoma","from":"hpv-associated-vulvar-cancer","refs":["pembrolizumab"]},{"group":"history","date":"2022","precision":"year","title":"Pluvicto approved; ARASENS establishes triplet therapy","note":"Prostate cancer","from":"prostate","refs":["pluvicto","arasens","darolutamide"]},{"group":"history","date":"2022","precision":"year","title":"POLARIX: first frontline improvement on R-CHOP in twenty years; CAR-T approved second line","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["polarix","polatuzumab-vedotin","axicabtagene-ciloleucel"]},{"group":"history","date":"2022","precision":"year","title":"PRODIGE 24 at five years: median survival 53.5 months","note":"Pancreatic ductal adenocarcinoma. Adjuvant modified FOLFIRINOX against gemcitabine: median overall survival 53.5 versus 35.5 months, five-year survival 43.2 versus 31.4 percent, ha...","from":"pancreatic","refs":["paper-prodige-24-five-year-outcomes-jama-oncol-2022","prodige-24"]},{"group":"history","date":"2022","precision":"year","title":"PROpel and MAGNITUDE: PARP inhibitor plus abiraterone","note":"Metastatic castration-resistant prostate cancer","from":"prostate-mcrpc","refs":["propel","magnitude"]},{"group":"history","date":"2022","precision":"year","title":"RAINBO NSMP-ORANGE opens: progestin versus chemotherapy after surgery","note":"Endometrial cancer with no specific molecular profile","from":"endometrial-nsmp","refs":[]},{"group":"history","date":"2022","precision":"year","title":"RAINBO programme opens, with POLEmut-BLUE testing de-escalation","note":"POLE-ultramutated endometrial cancer","from":"endometrial-pole-ultramutated","refs":[]},{"group":"history","date":"2022","precision":"year","title":"Randomised phase 2: axitinib delays progression versus observation","note":"Adenoid cystic carcinoma","from":"adenoid-cystic-carcinoma","refs":["axitinib"]},{"group":"history","date":"2022","precision":"year","title":"rEECur: high-dose ifosfamide best of four relapse regimens","note":"Ewing sarcoma","from":"ewing-sarcoma","refs":["ifosfamide"]},{"group":"history","date":"2022","precision":"year","title":"RELATIVITY-047: nivolumab plus relatlimab approved; Dutch trial shows TIL beats ipilimumab","note":"Advanced melanoma (unresectable stage III and stage IV)","from":"advanced-melanoma","refs":["relativity-047","relatlimab-nivolumab","til-therapy"]},{"group":"history","date":"2022","precision":"year","title":"SEQUOIA: zanubrutinib beats bendamustine-rituximab; GLOW: ibrutinib-venetoclax approved in Europe","note":"Chronic lymphocytic leukaemia, first treatment","from":"cll-treatment-naive","refs":["sequoia","zanubrutinib","glow"]},{"group":"history","date":"2022","precision":"year","title":"STAMPEDE: abiraterone improves survival in high-risk non-metastatic disease","note":"Localised prostate cancer, high and very high risk","from":"prostate-high-risk","refs":["stampede","abiraterone"]},{"group":"history","date":"2022","precision":"year","title":"SWOG S1801: three doses before surgery beat the same drug given only after","note":"Stage III melanoma (after surgery)","from":"stage-iii-melanoma","refs":["swog-s1801"]},{"group":"history","date":"2022","precision":"year","title":"Tabelecleucel approved in the EU","note":"Post-transplant lymphoproliferative disorder (PTLD). First allogeneic T-cell immunotherapy approved; December 2022, for relapsed or refractory EBV-positive PTLD.","from":"post-transplant-lymphoproliferative-disorder","refs":["allogeneic-cell-therapy"]},{"group":"history","date":"2022","precision":"year","title":"TAPPAS: TRC105 plus pazopanib fails to beat pazopanib","note":"Angiosarcoma","from":"angiosarcoma","refs":["pazopanib"]},{"group":"history","date":"2022","precision":"year","title":"Tebentafusp approved","note":"Uveal melanoma. FDA January 2022; EMA April 2022.","from":"uveal-melanoma","refs":["tebentafusp"]},{"group":"history","date":"2022","precision":"year","title":"Teclistamab: first BCMA bispecific approved (MajesTEC-1)","note":"Relapsed or refractory multiple myeloma","from":"myeloma-relapsed-refractory","refs":["teclistamab","majestec-1"]},{"group":"history","date":"2022","precision":"year","title":"Teclistamab: first myeloma bispecific","note":"Multiple myeloma","from":"multiple-myeloma","refs":["teclistamab"]},{"group":"history","date":"2022","precision":"year","title":"Teclistamab: first myeloma bispecific; cilta-cel approved","note":"Multiple myeloma","from":"multiple-myeloma","refs":["teclistamab","majestec-1","ciltacabtagene-autoleucel"]},{"group":"history","date":"2022","precision":"year","title":"The UK National Screening Committee recommends targeted screening","note":"Lung cancer (all types). After an evidence review and a health economic model, the committee recommended in June 2022 that all four UK nations move towards targeted lung cancer scr...","from":"lung-cancer","refs":[]},{"group":"history","date":"2022","precision":"year","title":"TOPAZ-1: durvalumab added to chemotherapy","note":"Gallbladder cancer. First immunotherapy survival benefit in biliary tract cancer; FDA approval September 2022.","from":"gallbladder","refs":["topaz-1","durvalumab"]},{"group":"history","date":"2022","precision":"year","title":"TOPAZ-1: durvalumab added to gemcitabine-cisplatin","note":"Extrahepatic cholangiocarcinoma (perihilar and distal)","from":"extrahepatic-cholangiocarcinoma","refs":["topaz-1","durvalumab"]},{"group":"history","date":"2022","precision":"year","title":"TOPAZ-1: first immunotherapy approval; futibatinib approved","note":"Biliary tract cancer (cholangiocarcinoma)","from":"cholangiocarcinoma","refs":["topaz-1","durvalumab","futibatinib","foenix-cca2"]},{"group":"history","date":"2022","precision":"year","title":"TOPAZ-1: immunotherapy first line","note":"Biliary tract cancer (cholangiocarcinoma)","from":"cholangiocarcinoma","refs":["durvalumab"]},{"group":"history","date":"2022","precision":"year","title":"Tumour-agnostic approval of dabrafenib plus trametinib for BRAF V600E solid tumours, including high-grade glioma","note":"Paediatric high-grade glioma (excluding diffuse midline glioma)","from":"paediatric-high-grade-glioma","refs":["dabrafenib-trametinib"]},{"group":"history","date":"2022","precision":"year","title":"TUXEDO-1 and DEBBRAH: trastuzumab deruxtecan active in the brain","note":"HER2-positive breast cancer with brain metastases","from":"her2-positive-breast-brain-metastases","refs":["trastuzumab-deruxtecan"]},{"group":"history","date":"2022","precision":"year","title":"WHO 5th edition and ICC redefine CMML","note":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms. Monocyte threshold lowered to 0.5 x 10^9/L with molecular support; dysplastic vs proliferative subtypes formalised.","from":"cmml","refs":[]},{"group":"history","date":"2022","precision":"year","title":"WHO and ICC classifications refine indolent, smouldering and bone marrow mastocytosis criteria","note":"Indolent and smouldering systemic mastocytosis","from":"indolent-systemic-mastocytosis","refs":[]},{"group":"history","date":"2022","precision":"year","title":"WHO and ICC classifications update advanced disease criteria","note":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","from":"advanced-systemic-mastocytosis","refs":["kit"]},{"group":"history","date":"2022","precision":"year","title":"WHO classification recognises SWI/SNF-deficient sinonasal carcinomas as separate entities","note":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","from":"sinonasal-undifferentiated-carcinoma","refs":[]},{"group":"history","date":"2022","precision":"year","title":"WHO classification refines carcinoma criteria","note":"Parathyroid carcinoma. Fifth edition endocrine tumours.","from":"parathyroid-carcinoma","refs":[]},{"group":"history","date":"2022","precision":"year","title":"WHO classification separates HPV-associated and HPV-independent penile squamous cell carcinoma","note":"Localised penile cancer (organ-confined, node-negative)","from":"localised-penile-cancer","refs":["hpv-p16"]},{"group":"history","date":"2022","precision":"year","title":"WHO classifies B-ALL with BCR::ABL1-like features as an entity","note":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","from":"all-ph-like","refs":[]},{"group":"history","date":"2022","precision":"year","title":"WHO drops type 1 and 2 in favour of molecular groups","note":"Papillary renal cell carcinoma","from":"papillary-rcc","refs":[]},{"group":"history","date":"2022","precision":"year","title":"WHO endorses single-dose HPV vaccination (KEN SHE); OUTBACK negative","note":"Cervical cancer","from":"cervical","refs":["ken-she","outback"]},{"group":"history","date":"2022","precision":"year","title":"WHO renames pituitary adenoma as PitNET","note":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma. Lineage-based classification.","from":"pituitary-tumours","refs":[]},{"group":"history","date":"2022","precision":"year","title":"WHO renames the disease nodular lymphocyte-predominant B-cell lymphoma","note":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","from":"nodular-lymphocyte-predominant-hodgkin-lymphoma","refs":["lymphoma-type"]},{"group":"history","date":"2022","precision":"year","title":"WHO separates oncocytic carcinoma from follicular cancer","note":"Follicular thyroid cancer","from":"follicular-thyroid-cancer","refs":[]},{"group":"history","date":"2022","precision":"year","title":"ZUMA-7: CAR-T beats transplant","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":[]},{"group":"journal","date":"2022","precision":"year","title":"Journal of pediatric hematology/oncology nursing founded","note":"SAGE Publications","from":"journal-of-pediatric-hematology-oncology-nursing","refs":[]},{"group":"journal","date":"2022","precision":"year","title":"NEJM Evidence founded","note":"NEJM Group / Massachusetts Medical Society","from":"nejm-evidence","refs":[]},{"group":"law","date":"2022","precision":"year","title":"FDORA 2022 accelerated approval reforms","note":"United States, statute.","from":"fdora-2022","refs":[]},{"group":"law","date":"2022","precision":"year","title":"Inflation Reduction Act 2022: Medicare drug price negotiation","note":"United States, statute.","from":"inflation-reduction-act","refs":[]},{"group":"law","date":"2022","precision":"year","title":"Innovative Medicines Fund (England)","note":"United Kingdom, scheme.","from":"innovative-medicines-fund","refs":[]},{"group":"law","date":"2022","precision":"year","title":"NICE technology appraisal methods (2022)","note":"United Kingdom, guidance.","from":"nice-methods","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"\"The emerging role of capivasertib in breast cancer\"","note":"Andrikopoulou A, Chatzinikolaou S, Panourgias E, et al. The Breast.","from":"paper-capivasertib-breast-hr-positive-breast-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology...","note":"Lyon AR, López-Fernández T, Couch LS, et al. European heart journal.","from":"paper-lyon-eur-heart-j","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"AALL1231: bortezomib in newly diagnosed T-cell acute lymphoblastic leukaemia and lymphoma, with cranial radiotherapy removed","note":"Teachey DT, Devidas M, Wood BL, et al. Journal of Clinical Oncology.","from":"paper-aall1231-bortezomib-t-all-teachey-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"AAML1031: sorafenib combined with chemotherapy for children with high allelic ratio FLT3-ITD acute myeloid leukaemia","note":"Pollard JA, Alonzo TA, Gerbing R, et al. Journal of Clinical Oncology.","from":"paper-aaml1031-sorafenib-flt3-pollard-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"AAPM task group report 302: Surface-guided radiotherapy","note":"Al-Hallaq HA, Cerviño L, Gutierrez AN, et al. Medical physics.","from":"paper-al-hallaq-med-phys","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","note":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. NEJM Evidence.","from":"paper-clarke-nejm-evid","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicen...","note":"Fizazi K, Foulon S, Carles J, et al. The Lancet.","from":"paper-peace-1-lancet-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"ACNS1123: response-based reduced-dose whole-ventricular radiotherapy for localised germinoma","note":"Bartels U, Onar-Thomas A, Patel SK, et al. Neuro-Oncology.","from":"paper-acns1123-germinoma-neuro-oncology-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Ch...","note":"Parsons DW, Janeway KA, Patton DR, et al. Journal of Clinical Oncology.","from":"paper-parsons-j-clin-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","note":"Jänne PA, Riely GJ, Gadgeel SM, et al. New England Journal of Medicine.","from":"paper-nct03785249-n-engl-j-med-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised...","note":"Wang J, Zhou C, Yao W, et al. The Lancet Oncology.","from":"paper-capstone-1-lancet-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EG...","note":"Lu S, Dong X, Jian H, et al. Journal of Clinical Oncology.","from":"paper-aeneas-j-clin-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in women of African de...","note":"Martini R, Delpe P, Chu TR, et al. Cancer Discovery.","from":"paper-martini-african-ancestry-tnbc-cancer-discov-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy","note":"Montesinos P, Recher C, Vives S, et al. New England Journal of Medicine.","from":"paper-agile-ivosidenib-azacitidine-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma","note":"Castellino SM, Pei Q, Parsons SK, et al. New England Journal of Medicine.","from":"paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer","note":"Katz MHG, Shi Q, Meyers J, et al. JAMA Oncology.","from":"paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"ANCHOR: treating anal high-grade squamous intraepithelial lesions to prevent anal cancer in people living with HIV","note":"Palefsky JM, Lee JY, Jay N, et al. New England Journal of Medicine.","from":"paper-anchor-anal-hsil-treatment-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2...","note":"Kindler HL, Novello S, Bearz A, et al. The Lancet Oncology.","from":"paper-kindler-lancet-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer","note":"Smith MR, Hussain M, Saad F, et al. New England Journal of Medicine.","from":"paper-arasens-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity","note":"Aminian A, Wilson R, Al-Kurd A, et al. JAMA.","from":"paper-aminian-jama","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade acr...","note":"Ricciuti B, Wang X, Alessi JV, et al. JAMA Oncology.","from":"paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study","note":"Friedman CF, Hainsworth JD, Kurzrock R, et al. Cancer Discovery.","from":"paper-friedman-cancer-discov","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized ph...","note":"Peters S, Dziadziuszko R, Morabito A, et al. Nature Medicine.","from":"paper-nct03178552-nat-med-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","note":"Reig M, Forner A, Rimola J, et al. Journal of Hepatology.","from":"paper-bclc-2022-reig-j-hepatol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update","note":"Andre F, Ismaila N, Allison KH, et al. Journal of Clinical Oncology.","from":"paper-andre-j-clin-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update","note":"Henry NL, Somerfield MR, Dayao Z, et al. Journal of Clinical Oncology.","from":"paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report","note":"Johnson SB, Parsons M, Dorff T, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-johnson-j-natl-cancer-inst","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89 Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Mi...","note":"Farwell MD, Gamache RF, Babazada H, et al. Journal of Nuclear Medicine.","from":"paper-farwell-j-nucl-med","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency","note":"Cercek A, Lumish M, Sinopoli J, et al. New England Journal of Medicine.","from":"paper-cercek-dostarlimab-rectal-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","note":"Upadhaya S, Neftelinov ST, Hodge J, et al. Nature Reviews Drug Discovery.","from":"paper-upadhaya-nat-rev-drug-discov","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19","note":"Hoang R, Temple C, Correia MS, Clemons J, Hendrickson RG. Clinical Toxicology.","from":"paper-hoang-ivermectin-toxicity-clin-toxicol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma","note":"Doki Y, Ajani JA, Kato K, et al. New England Journal of Medicine.","from":"paper-checkmate-648-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","note":"Forde PM, Spicer J, Lu S, et al. New England Journal of Medicine.","from":"paper-checkmate-816-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","note":"Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, et al. Frontiers in immunology.","from":"paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical beh...","note":"Henriksen TV, Tarazona N, Frydendahl A, et al. Clinical Cancer Research.","from":"paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stag...","note":"Herbst RS, Majem M, Barlesi F, et al. Journal of Clinical Oncology.","from":"paper-herbst-j-clin-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","note":"Giraldo NA, Drill E, Satravada BA, et al. Clinical Cancer Research.","from":"paper-giraldo-gallbladder-msk-impact-ccr-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Cost-efficient whole genome-sequencing using novel mostly natural sequencing-by-synthesis chemistry and open fluidics platform","note":"Almogy G, Pratt M, Oberstrass F, et al. bioRxiv (preprint).","from":"paper-almogy-biorxiv","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","note":"Subbiah V, Kreitman RJ, Wainberg ZA, et al. Annals of Oncology.","from":"paper-roar-ann-oncol-2022-update","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","note":"Cortes J, Kim SB, Chung WP, et al. New England Journal of Medicine.","from":"paper-destiny-breast03-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","note":"Modi S, Jacot W, Yamashita T, et al. New England Journal of Medicine.","from":"paper-destiny-breast04-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","note":"Li BT, Smit EF, Goto Y, et al. New England Journal of Medicine.","from":"paper-destiny-lung01-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis","note":"Berchuck JE, Baca SC, McClure HM, et al. Clinical Cancer Research.","from":"paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Differences in prostate cancer genomes by self-reported race","note":"Stopsack KH, Nandakumar S, Arora K, et al. Clinical Cancer Research.","from":"paper-stopsack-prostate-genomes-by-race-ccr-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","note":"Ricciuti B, Arbour KC, Lin JJ, et al. Journal of Thoracic Oncology.","from":"paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","note":"Tie J, Cohen JD, Lahouel K, et al. New England Journal of Medicine.","from":"paper-dynamic-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Early detection of cancer","note":"Crosby D, Bhatia S, Brindle KM, et al. Science.","from":"paper-crosby-science","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"ECOG-ACRIN E3311: transoral surgery followed by reduced-dose radiotherapy for HPV-positive oropharyngeal cancer","note":"Ferris RL, Flamand Y, Weinstein GS, et al. Journal of Clinical Oncology.","from":"paper-e3311-transoral-surgery-ferris-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial","note":"Basch E, Schrag D, Henson S, et al. JAMA.","from":"paper-basch-jama","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized...","note":"Cheng Y, Han L, Wu L, et al. JAMA.","from":"paper-astrum-005-jama-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial","note":"Goodwin PJ, Chen BE, Gelmon KA, et al. JAMA.","from":"paper-goodwin-jama","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial","note":"Pellacani G, Farnetani F, Ciardo S, et al. JAMA dermatology.","from":"paper-pellacani-jama-dermatol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","note":"Post CCB, Westermann AM, Boere IA, et al. Gynecologic Oncology.","from":"paper-durvalumab-endometrial-gynecol-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Efficacy of single-dose HPV vaccination among young African women","note":"Barnabas RV, Brown ER, Onono MA, et al. NEJM Evidence.","from":"paper-barnabas-nejm-evid","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"ELN 2022: diagnosis and management of acute myeloid leukaemia in adults","note":"Döhner H, Wei AH, Appelbaum FR, et al. Blood.","from":"paper-eln-2022-aml-dohner-blood-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"EMERALD: elacestrant versus standard endocrine therapy after a CDK4/6 inhibitor","note":"Bidard FC, Kaklamani VG, Neven P, et al. Journal of Clinical Oncology.","from":"paper-emerald-elacestrant-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum","note":"Tewari KS, Monk BJ, Vergote I, et al. New England Journal of Medicine.","from":"paper-empower-cervical-1-cemiplimab-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Endometrial cancer","note":"Crosbie EJ, Kitson SJ, McAlpine JN, et al. The Lancet.","from":"paper-crosbie-lancet","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"ESTIMABL2: thyroidectomy without radioiodine in patients with low-risk thyroid cancer","note":"Leboulleux S, Bournaud C, Chougnet CN, et al. New England Journal of Medicine.","from":"paper-estimabl2-leboulleux-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ)","note":"Babjuk M, Burger M, Capoun O, et al. European Urology.","from":"paper-eau-nmibc-guideline-eur-urol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue","note":"Fernandez AI, Liu M, Bellizzi A, et al. JAMA Oncology.","from":"paper-fernandez-jama-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal...","note":"Brown LC, Graham J, Fisher D, et al. Clinical trials (London, England).","from":"paper-brown-clin-trials","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications","note":"Stockwell BR. Cell.","from":"paper-stockwell-cell","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase...","note":"Zhang L, Wang Z, Fang J, et al. Lung cancer.","from":"paper-orient-11-lung-cancer-2022-update","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial","note":"Conroy T, Castan F, Lopez A, et al. JAMA Oncology.","from":"paper-prodige-24-five-year-outcomes-jama-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","note":"Spigel DR, Faivre-Finn C, Gray JE, et al. Journal of Clinical Oncology.","from":"paper-spigel-pacific-five-year-survival-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative br...","note":"Howell SJ, Casbard A, Carucci M, et al. The Lancet Oncology.","from":"paper-capivasertib-breast-hr-positive-lancet-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders","note":"Kornauth C, Pemovska T, Vladimer GI, et al. Cancer Discovery.","from":"paper-kornauth-cancer-discov","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lu...","note":"Shi Y, Chen G, Wang X, et al. The Lancet. Respiratory medicine.","from":"paper-furlong-lancet-respir-med-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Gallbladder cancer","note":"Roa JC, García P, Kapoor VK, et al. Nature Reviews Disease Primers.","from":"paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","note":"Casali PG, Blay JY, Abecassis N, et al. Annals of Oncology.","from":"paper-casali-ann-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","note":"Majzner RG, Ramakrishna S, Yeom KW, et al. Nature.","from":"paper-majzner-nature","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","note":"Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. New England Journal of Medicine.","from":"paper-glofitamab-dlbcl-n-engl-j-med-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer","note":"Gershenson DM, Miller A, Brady WE, et al. The Lancet.","from":"paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"GOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma","note":"Powell MA, Filiaci VL, Hensley ML, et al. Journal of Clinical Oncology.","from":"paper-gog-0261-carcinosarcoma-powell-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells","note":"Hanahan D. Cancer Discovery.","from":"paper-hallmarks-new-dimensions-cancer-discov-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Hallmarks of DNA replication stress","note":"Saxena S, Zou L. Molecular cell.","from":"paper-saxena-mol-cell","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Hietanen 2022: the marketed oncolytic virus Rigvir was no more oncolytic than any other echovirus isolate","note":"Hietanen E, Koivu MKA, Susi P. Viruses.","from":"paper-hietanen-rigvir-echovirus-viruses-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"HIMALAYA: tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","note":"Abou-Alfa GK, Lau G, Kudo M, et al. NEJM Evidence.","from":"paper-himalaya-nejm-evidence-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time...","note":"Cai L, Tao T, Li H, et al. Journal of global health.","from":"paper-cai-j-glob-health","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Increasing incidence of early-onset colorectal cancer (review)","note":"Sinicrope FA. New England Journal of Medicine.","from":"paper-sinicrope-early-onset-crc-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline","note":"Mao JJ, Ismaila N, Bao T, et al. Journal of Clinical Oncology.","from":"paper-mao-j-clin-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, pha...","note":"Tree AC, Ostler P, van der Voet H, et al. The Lancet Oncology.","from":"paper-pace-b-lancet-oncol-2022-update","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)","note":"Arber DA, Orazi A, Hasserjian RP, et al. Blood.","from":"paper-icc-2022-arber-blood-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib","note":"Bauer S, Jones RL, Blay JY, et al. Journal of Clinical Oncology.","from":"paper-intrigue-ripretinib-vs-sunitinib-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"IPSS-M: the molecular international prognostic scoring system for myelodysplastic syndromes","note":"Bernard E, Tuechler H, Greenberg PL, et al. NEJM Evidence.","from":"paper-ipss-m-bernard-nejm-evidence-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"KEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer","note":"Cortes J, Rugo HS, Cescon DW, et al. New England Journal of Medicine.","from":"paper-keynote-355-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","note":"Schmid P, Cortes J, Dent R, et al. New England Journal of Medicine.","from":"paper-keynote-522-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"KEYNOTE-716: adjuvant pembrolizumab versus placebo in completely resected stage IIB or IIC melanoma","note":"Luke JJ, Rutkowski P, Queirolo P, et al. The Lancet.","from":"paper-keynote-716-lancet-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer","note":"Makker V, Colombo N, Casado Herráez A, et al. New England Journal of Medicine.","from":"paper-keynote-775-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma","note":"Pautier P, Italiano A, Piperno-Neumann S, et al. The Lancet Oncology.","from":"paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year...","note":"Geyer CE, Sikov WM, Huober J, et al. Annals of Oncology.","from":"paper-geyer-brightness-4-year-follow-up-ann-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 rand...","note":"Ferreri AJM, Cwynarski K, Pulczynski E, et al. Leukemia.","from":"paper-ferreri-leukemia","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Lutetium-177 DOTATATE: A Practical Review","note":"Jia AY, Kashani R, Zaorsky NG, et al. Practical radiation oncology.","from":"paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma","note":"Moreau P, Garfall AL, van de Donk NWCJ, et al. New England Journal of Medicine.","from":"paper-majestec-1-teclistamab-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE","note":"Foley KG, Lahaye MJ, Thoeni RF, et al. European Radiology.","from":"paper-gallbladder-polyp-joint-guideline-eur-radiol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","note":"Haanen J, Obeid M, Spain L, et al. Annals of Oncology.","from":"paper-haanen-ann-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","note":"Philip PA, Azar I, Xiu J, et al. Clinical Cancer Research.","from":"paper-philip-kras-wild-type-pancreatic-ccr-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma","note":"Chari A, Minnema MC, Berdeja JG, et al. New England Journal of Medicine.","from":"paper-monumental-1-talquetamab-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","note":"Marron TU, Fiel MI, Hamon P, et al. The lancet. Gastroenterology & hepatology.","from":"paper-nct03916627-lancet-gastroenterol-hepatol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma","note":"Gross ND, Miller DM, Khushalani NI, et al. New England Journal of Medicine.","from":"paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test","note":"Neal RD, Johnson P, Clarke CA, et al. Cancers.","from":"paper-nhs-galleri-design-cancers-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","note":"Dizman N, Meza L, Bergerot P, et al. Nature Medicine.","from":"paper-dizman-nat-med","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected","note":"Bretthauer M, Løberg M, Wieszczy P, et al. New England Journal of Medicine.","from":"paper-nordicc-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)","note":"Garcia-Aguilar J, Patil S, Gollub MJ, et al. Journal of Clinical Oncology.","from":"paper-garcia-aguilar-opra-organ-preservation-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","note":"Geyer CE, Garber JE, Gelber RD, et al. Annals of Oncology.","from":"paper-olympia-overall-survival-ann-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","note":"Hortobagyi GN, Stemmer SM, Burris HA, et al. New England Journal of Medicine.","from":"paper-monaleesa-2-n-engl-j-med-2022-update","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade","note":"Alausa A, Lawal KA, Babatunde OA, et al. Pharmacological research.","from":"paper-cd47-pancreatic-pharmacol-res-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","note":"Maio M, Ascierto PA, Manzyuk L, et al. Annals of Oncology.","from":"paper-keynote-158-ann-oncol-2022-update","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","note":"O'Malley DM, Bariani GM, Cassier PA, et al. Journal of Clinical Oncology.","from":"paper-antoine-italiano-j-clin-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365...","note":"Yu EY, Kolinsky MP, Berry WR, et al. European Urology.","from":"paper-nct02861573-eur-urol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of...","note":"Diaz LA, Shiu KK, Kim TW, et al. The Lancet Oncology.","from":"paper-keynote-177-lancet-oncol-2022-update","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre...","note":"Long GV, Luke JJ, Khattak MA, et al. The Lancet Oncology.","from":"paper-keynote-716-lancet-oncol-2022-update","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study","note":"Gupta R, Meric-Bernstam F, Rothe M, et al. JCO Precision Oncology.","from":"paper-gupta-jco-precis-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-...","note":"Reckamp KL, Redman MW, Dragnev KH, et al. Journal of Clinical Oncology.","from":"paper-reckamp-j-clin-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E...","note":"Eckstein OS, Allen CE, Williams PM, et al. Journal of Clinical Oncology.","from":"paper-eckstein-j-clin-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","note":"Lim M, Weller M, Idbaih A, et al. Neuro-Oncology.","from":"paper-lim-neuro-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","note":"Tilly H, Morschhauser F, Sehn LH, et al. New England Journal of Medicine.","from":"paper-polarix-polatuzumab-rchp-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer","note":"Kindler HL, Hammel P, Reni M, et al. Journal of Clinical Oncology.","from":"paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","note":"Powell CA, Modi S, Iwata H, et al. ESMO Open.","from":"paper-powell-esmo-open","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab","note":"Ligorio F, Di Cosimo S, Verderio P, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-luca-gianni-j-natl-cancer-inst-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer","note":"Versteijne E, van Dam JL, Suker M, et al. Journal of Clinical Oncology.","from":"paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only","note":"Hugosson J, Månsson M, Wallström J, et al. New England Journal of Medicine.","from":"paper-goteborg-2-n-engl-j-med-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","note":"Esteva A, Feng J, van der Wal D, et al. NPJ digital medicine.","from":"paper-esteva-npj-digit-med","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"PROTAC targeted protein degraders: the past is prologue","note":"Békés M, Langley DR, Crews CM. Nature Reviews Drug Discovery.","from":"paper-bekes-nat-rev-drug-discov","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","note":"Parker CC, James ND, Brawley CD, et al. PLOS Medicine.","from":"paper-stampede-plos-med-2022-update","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)","note":"Kehl KL, Zahrieh D, Yang P, et al. JAMA Oncology.","from":"paper-alchemist-jama-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma","note":"Tawbi HA, Schadendorf D, Lipson EJ, et al. New England Journal of Medicine.","from":"paper-relativity-047-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","note":"Yau C, Osdoit M, van der Noordaa M, et al. The Lancet Oncology.","from":"paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","note":"Rohaas MW, Borch TH, van den Berg JH, et al. New England Journal of Medicine.","from":"paper-rohaas-til-vs-ipilimumab-nejm-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","note":"van Herpen C, Vander Poorten V, Skalova A, et al. ESMO Open.","from":"paper-van-herpen-esmo-open","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Senescence and cancer - role and therapeutic opportunities","note":"Schmitt CA, Wang B, Demaria M. Nature Reviews Clinical Oncology.","from":"paper-schmitt-nat-rev-clin-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Siegel 2022: Cancer statistics, 2022","note":"Siegel RL, Miller KD, Fuchs HE, Jemal A. CA: A Cancer Journal for Clinicians.","from":"paper-siegel-cancer-statistics-2022-cacancer-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer","note":"Attard G, Murphy L, Clarke NW, et al. The Lancet.","from":"paper-stampede-abiraterone-high-risk-attard-lancet-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): in...","note":"Zhou C, Wang Z, Sun Y, et al. The Lancet Oncology.","from":"paper-gemstone-302-lancet-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Synergistic anti-tumor effect of dichloroacetate and ivermectin","note":"Ishiguro T, Ishiguro RH, Ishiguro M, Toki A, Terunuma H. Cureus.","from":"paper-ishiguro-dichloroacetate-ivermectin-cureus-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"The 2021 WHO classification of tumours of the thymus and mediastinum: what is new in thymic epithelial, germ cell and mesenchymal tumours","note":"Marx A, Chan JKC, Chalabreysse L, et al. Journal of Thoracic Oncology.","from":"paper-who-2021-thymus-mediastinum-classification-marx-jto-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"The hallmarks of cancer metabolism: Still emerging","note":"Pavlova NN, Zhu J, Thompson CB. Cell metabolism.","from":"paper-pavlova-cell-metab-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival","note":"Dbouk M, Katona BW, Brand RE, et al. Journal of Clinical Oncology.","from":"paper-dbouk-caps5-stage-survival-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","note":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, et al. Nature Reviews Clinical Oncology.","from":"paper-dhanasekaran-nat-rev-clin-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and...","note":"Cho BC, Abreu DR, Hussein M, et al. The Lancet Oncology.","from":"paper-cho-lancet-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III...","note":"Shen L, Kato K, Kim SB, et al. Journal of Clinical Oncology.","from":"paper-shen-j-clin-oncol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Todo 2022: the triple-mutated herpes virus that became Japan's first approved oncolytic virus","note":"Todo T, Ito H, Ino Y, et al. Nature Medicine.","from":"paper-todo-g47delta-glioblastoma-natmed-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"TOPAZ-1: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","note":"Oh DY, Ruth He A, Qin S, et al. NEJM Evidence.","from":"paper-topaz-1-nejm-evidence-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","note":"Wang ZX, Cui C, Yao J, et al. Cancer Cell.","from":"paper-wang-cancer-cell","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation...","note":"Rosen DB, Kvarnhammar AM, Laufer B, et al. Journal for ImmunoTherapy of Cancer.","from":"paper-nct05081609-j-immunother-cancer-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma","note":"Kamdar M, Solomon SR, Arnason J, et al. The Lancet.","from":"paper-transform-liso-cel-lancet-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-...","note":"Krop IE, Im SA, Barrios C, et al. Journal of Clinical Oncology.","from":"paper-luca-gianni-j-clin-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","note":"Vogelbaum MA, Brown PD, Messersmith H, et al. Journal of Clinical Oncology.","from":"paper-andrew-lassman-j-clin-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases","note":"Bartsch R, Berghoff AS, Furtner J, et al. Nature Medicine.","from":"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","note":"Cheng AL, Qin S, Ikeda M, et al. Journal of hepatology.","from":"paper-atezolizumab-hcc-j-hepatol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation U...","note":"Korde LA, Somerfield MR, Hershman DL, et al. Journal of Clinical Oncology.","from":"paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma","note":"Chalasani NP, Porter K, Bhattacharya A, et al. Clinical gastroenterology and hepatology.","from":"paper-chalasani-clin-gastroenterol-hepatol","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms","note":"Alaggio R, Amador C, Anagnostopoulos I, et al. Leukemia.","from":"paper-who-2022-lymphoid-alaggio-leukemia-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms","note":"Khoury JD, Solary E, Abla O, et al. Leukemia.","from":"paper-who-2022-myeloid-khoury-leukemia-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"WHO classification of tumours of the urinary system and male genital organs, 2022: renal, penile and testicular tumours","note":"Moch H, Amin MB, Berney DM, et al. European Urology.","from":"paper-who-2022-gu-moch-eur-urol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, ph...","note":"Tam CS, Brown JR, Kahl BS, et al. The Lancet Oncology.","from":"paper-zanubrutinib-cll-lancet-oncol-2022","refs":[]},{"group":"paper","date":"2022","precision":"year","title":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","note":"Locke FL, Miklos DB, Jacobson CA, et al. New England Journal of Medicine.","from":"paper-zuma-7-axi-cel-second-line-nejm-2022","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"A national precision cancer medicine implementation initiative for Norway","note":"Nature Medicine","from":"kjetil-tasken","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castrat...","note":"Future Oncology","from":"neeraj-agarwal","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"A Translational Randomized Trial of Perioperative Arginine Immunonutrition on Natural Killer Cell Function in Colorectal Cancer Surgery Patients","note":"Annals of Surgical Oncology","from":"rebecca-auer","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1)","note":"Lancet","from":"karim-fizazi","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?","note":"The Lancet Oncology","from":"nicole-scobie","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)","note":"Journal of Clinical Oncology","from":"michael-gnant","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Advances in oncolytic virotherapy","note":"Communications Medicine","from":"john-bell","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models","note":"Nucleic Acids Research","from":"ewan-birney","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","note":"Lancet Oncology","from":"amar-kishan","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","note":"New England Journal of Medicine","from":"frederick-locke","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Barriers and facilitators to provide multidisciplinary care for breast cancer patients in five Latin American countries: A descriptive-interpretative qualitativ...","note":"The Lancet Regional Health - Americas","from":"barrios-carlos","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT)","note":"Lancet Oncology","from":"zev-wainberg","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma (AHOD1331)","note":"NEJM","from":"kara-kelly","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Cancer incidence estimates for 2022 and projection for 2025: result from National Cancer Registry Programme, India","note":"Indian Journal of Medical Research","from":"mathur-prashant","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","note":"Journal of Hematology & Oncology","from":"wei-yuquan","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Cancer‐related mortality among people with intellectual disabilities: A nationwide population‐based cohort study","note":"Cancer","from":"geraline-leusink","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Carbon‐ion radiotherapy for urological cancers","note":"International Journal of Urology","from":"hitoshi-ishikawa","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas","note":"Nature Communications","from":"eliane-piaggio","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Chronic treatment of COPD: state of the art and real-world analysis of healthcare costs based on medication adherence data","note":"Recenti Progressi in Medicina","from":"alessandro-delle-donne","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer (DYNAMIC)","note":"NEJM","from":"jeanne-tie","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","note":"Nature Medicine","from":"shen-lin","refs":["qi-changsong","li-zonghai"]},{"group":"person-paper","date":"2022","precision":"year","title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","note":"Nature Medicine","from":"enrique-espinosa","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703...","note":"Journal of Clinical Oncology","from":"alexis-cortot","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada","note":"JAMA Network Open","from":"jon-irish","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare...","note":"Annals of Oncology","from":"hanno-glimm","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Current and future colorectal cancer screening strategies","note":"Nature Reviews Gastroenterology & Hepatology","from":"theodore-levin","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer (ARASENS)","note":"NEJM","from":"matthew-smith","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","note":"Nature","from":"david-porter","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Development and validation of a population-based risk stratification model for severe COVID-19 in the general population","note":"Scientific Reports","from":"adria-comella-carnice","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","note":"Blood","from":"konstanze-doehner","refs":["hartmut-dohner"]},{"group":"person-paper","date":"2022","precision":"year","title":"Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America","note":"PLoS ONE","from":"carolina-wiesner","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1)","note":"NEJM Evidence","from":"oh-do-youn","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Effect of colonoscopy screening on risks of colorectal cancer and related death (NordICC)","note":"NEJM","from":"michael-bretthauer","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial (PRO-TECT)","note":"JAMA","from":"ethan-basch","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer","note":"Science Advances","from":"naoto-ueno","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer (...","note":"JCO","from":"aditya-bardia","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Elacestrant versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer (EMERALD)","note":"JCO","from":"francois-clement-bidard","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Enrollment Matters: The Reality of Disparity and Pursuit of Equity in Clinical Trials","note":"Cancer Discovery","from":"robert-winn","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Establishing a benchmark of diversity, equity, inclusion and workforce engagement in radiation oncology in Europe – An ESTRO collaborative project","note":"Radiotherapy and Oncology","from":"barbara-jereczek-fossa","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer","note":"JAMA Oncology","from":"mariana-chavez-macgregor","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cance...","note":"ESMO Open","from":"barrios-carlos","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate...","note":"JCO","from":"heinz-josef-lenz","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Five-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK","note":"Lancet Oncology","from":"shankar-siva","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","note":"Blood","from":"william-wierda","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","note":"Annals of Oncology","from":"florian-lordick","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-...","note":"The Lancet Gastroenterology & Hepatology","from":"kim-tae-you","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Genomics to select treatment for patients with metastatic breast cancer (SAFIR02-BREAST)","note":"Nature","from":"fabrice-andre","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Global Forum of Cancer Surgeons: Cancer Surgery During the COVID-19 Pandemic: Impact and Lessons Learned","note":"Annals of Surgical Oncology","from":"isabel-rubio","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma","note":"European Journal of Nuclear Medicine and Molecular Imaging","from":"song-shaoli","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"High Risk of Low Anterior Resection Syndrome in Long-term Follow-up After Anastomotic Leakage in Anterior Resection for Rectal Cancer","note":"Dis Colon Rectum","from":"pamela-buchwald","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"How we Treat HR-Positive, HER2-Negative Early Breast Cancer","note":"Future Oncology","from":"sara-lopez-tarruella","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Immunogenicity of two doses of inactive COVID‐19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy","note":"International Journal of Cancer","from":"kadir-mutlu-hayran","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Immunotherapy in surgical oncology","note":"British Journal of Surgery","from":"david-fennelly","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Impact of COVID-19 on access to cancer care in Rwanda: a retrospective time-series study using electronic medical records data","note":"BMJ Open","from":"nadine-karema","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-bas...","note":"Gastroenterology","from":"theodore-levin","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientif...","note":"ESMO Open","from":"anna-sapino","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis","note":"Journal of Clinical Oncology","from":"jimmy-so","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Intratumoral oncolytic herpes virus G47 delta for residual or recurrent glioblastoma: a phase 2 trial","note":"Nature Medicine","from":"tomoki-todo","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Is early-onset cancer an emerging global epidemic? Current evidence and future implications","note":"Nature Reviews Clinical Oncology","from":"weiderpass-elisabete","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tum...","note":"Journal of Clinical Oncology","from":"denis-lacombe","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer","note":"JAMA Surgery","from":"ziyu-li","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","note":"Journal for ImmunoTherapy of Cancer","from":"xia-michelle","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","note":"JCO","from":"jedd-wolchok","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021","note":"European Urology","from":"silke-gillessen","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline","note":"Journal of Clinical Oncology","from":"charles-simone","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer","note":"Cancers","from":"alinta-hegmane","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses","note":"Science Translational Medicine","from":"kunle-odunsi","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Microbiome and Development of Ovarian Cancer","note":"Endocrine, Metabolic & Immune Disorders - Drug Targets","from":"shalini-singh","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","note":"Blood","from":"sirpa-leppa","refs":["sirkku-jyrkkio"]},{"group":"person-paper","date":"2022","precision":"year","title":"Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy","note":"Nature Communications","from":"j-silvio-gutkind","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"MR relaxation times of agar-based tissue-mimicking phantoms","note":"J Appl Clin Med Phys","from":"nikolaos-zamboglou","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"MRD detection in a variety of cancers at unprecedented sensitivity with MAESTRO (minor allele enriched sequencing through recognition oligonucleotides)","note":"Nature Communications","from":"viktor-adalsteinsson","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Narrative Review of High-Dose-Rate Interstitial Brachytherapy in Primary or Secondary Liver Tumors","note":"Front Oncol","from":"nikolaos-zamboglou","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOP...","note":"JCO","from":"marc-besselink","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","note":"New England Journal of Medicine","from":"lu-shun","refs":["patrick-forde"]},{"group":"person-paper","date":"2022","precision":"year","title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer (CheckMate 816)","note":"NEJM","from":"jonathan-spicer","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"New insights into the genetic etiology of Alzheimer's disease and related dementias","note":"Nat Genet","from":"arto-mannermaa","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma (CheckMate 648)","note":"NEJM","from":"jaffer-ajani","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC","note":"Frontiers in Immunology","from":"li-weimin","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Nosocomial Transmission of SARS-CoV-2 Involving Vaccinated Health Care Workers","note":"Microbiology Spectrum","from":"sonia-garcia-de-san-jose","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Oncological liver resection in elderly – A retrospective comparative study","note":"International Journal of Surgery","from":"jurgen-weitz","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","note":"NEJM","from":"joseph-connors","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Palliative care to cancer patients: how COVID-19 pandemic could affect quality of care","note":"einstein (São Paulo)","from":"kaliks-rafael","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial","note":"European Respiratory Journal","from":"matthew-callister","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","note":"New England Journal of Medicine","from":"andrea-cercek","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716)","note":"Lancet","from":"dirk-schadendorf","refs":["jason-luke"]},{"group":"person-paper","date":"2022","precision":"year","title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX)","note":"NEJM","from":"gilles-salles","refs":["herve-tilly"]},{"group":"person-paper","date":"2022","precision":"year","title":"Precision medicine in non-small cell lung cancer: Current applications and future directions","note":"Seminars in Cancer Biology","from":"reinhard-buettner","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Priorities for cancer research in low- and middle-income countries: a global perspective","note":"Nature Medicine","from":"victor-piana-de-andrade","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Procedural Pain Assessment in Infants Without Analgosedation: Comparison of Newborn Infant Parasympathetic Evaluation and Skin Conductance Activity - A Pilot St...","note":"Frontiers in Pediatrics","from":"iwona-maroszynska","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Sys...","note":"Journal of Clinical Oncology","from":"sabine-linn","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagno...","note":"Trials","from":"narula-gaurav","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Real-world cost-effectiveness of population-based BRCA screening in Israel","note":"Cancers","from":"rachel-michaelson-cohen","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value","note":"Clin Pharmacol Ther","from":"emer-cooke","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Regulome analysis in B-acute lymphoblastic leukemia exposes Core Binding Factor addiction as a therapeutic vulnerability","note":"Nature Communications","from":"tariq-enver","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma (RELATIVITY-047)","note":"NEJM","from":"hussein-tawbi","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Risk Reversal of Oral, Pharyngeal and Oesophageal Cancers after Cessation of Betel Quid Users: A Systematic Review and Meta-Analysis","note":"Annals of Global Health","from":"shalini-singh","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Role of ubiquitin-protein ligase UBR5 in the disassembly of mitotic checkpoint complexes","from":"avram-hershko","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer","note":"Journal of Clinical Oncology","from":"hope-rugo","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","note":"New England Journal of Medicine","from":"armando-santoro","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, contro...","note":"The Lancet","from":"fukuda-haruhiko","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer","note":"Cancer Discovery","from":"jimmy-so","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment","note":"Cell Reports","from":"christian-capitini","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (P...","note":"Lancet Oncology","from":"francois-clement-bidard","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Systematic review and meta-analysis of randomized controlled trials comparing elective neck dissection versus sentinel lymph node biopsy in early-stage clinical...","note":"Oral Oncology","from":"chaturvedi-pankaj","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma (MonumenTAL-1)","note":"NEJM","from":"ajai-chari","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Teclistamab in relapsed or refractory multiple myeloma","note":"New England Journal of Medicine","from":"saad-usmani","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Teclistamab in relapsed or refractory multiple myeloma (MajesTEC-1)","note":"NEJM","from":"philippe-moreau","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young peopl...","note":"BMJ Open","from":"ashley-ball-gamble","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","note":"Annals of Oncology","from":"steven-horwitz","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer","note":"Int J Mol Sci","from":"ivan-s-stilidi","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"The IAEA’s Rays of Hope leverages nuclear science and collaboration to fight cancer in developing countries","note":"Journal of Cancer Policy","from":"rafael-mariano-grossi","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils...","note":"Journal of Experimental & Clinical Cancer Research","from":"antonio-rosato","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology","note":"Expert Review of Pharmacoeconomics & Outcomes Research","from":"beata-jagielska","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"The journey to pharmacy residency program accreditation: The Children’s Cancer Hospital–Egypt experience","note":"American Journal of Health-System Pharmacy","from":"sherif-abouel-naga","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Thyroidectomy without radioiodine in patients with low-risk thyroid cancer (ESTIMABL2)","note":"NEJM","from":"martin-schlumberger","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Toripalimab plus paclitaxel and cisplatin as first-line treatment for advanced oesophageal squamous cell carcinoma (JUPITER-06)","note":"Cancer Cell","from":"xu-rui-hua","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicen...","note":"The Lancet","from":"charlie-gourley","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia","note":"Leukemia","from":"christian-brandts","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","note":"New England Journal of Medicine","from":"bob-li","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer (DESTINY-Breast04)","note":"NEJM","from":"shanu-modi","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer (DESTINY-Breast03)","note":"NEJM","from":"javier-cortes","refs":["ian-krop"]},{"group":"person-paper","date":"2022","precision":"year","title":"Trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive metastatic breast cancer (DESTINY-Breast03)","note":"NEJM","from":"kim-sung-bae","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Treatment with tumor-infiltrating lymphocytes or ipilimumab in advanced melanoma","note":"NEJM","from":"john-haanen","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (HIMALAYA)","note":"NEJM Evidence","from":"ghassan-abou-alfa","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","note":"New England Journal of Medicine","from":"paul-richardson","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","note":"NEJM","from":"inge-marie-svane","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Use of geriatric assessment in cancer clinical trials: A systematic review","note":"Journal of Geriatric Oncology","from":"beth-devine","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Use of information and communication technologies (ICTs) in cancer multidisciplinary team meetings: an explorative study based on EU healthcare professionals","note":"BMJ Open","from":"claudio-lombardo","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy – an ancillary stud...","note":"Annals of Oncology","from":"daniel-aebersold","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","note":"Blood","from":"sascha-dietrich","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Weiterentwicklung und Vernetzung der onkologischen Versorgungsstrukturen, der Qualitätssicherung und der Forschung","note":"Das Gesundheitswesen","from":"thomas-kaiser","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","note":"Blood","from":"yuqin-song","refs":[]},{"group":"person-paper","date":"2022","precision":"year","title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)","note":"Lancet Oncology","from":"constantine-tam","refs":[]},{"group":"technology","date":"2022","precision":"year","title":"Ex vivo drug sensitivity screening in blood cancers (EXALT)","note":"First use in humans or first approval, as the technology record states it.","from":"functional-precision-medicine-haematology","refs":[]},{"group":"technology","date":"2022","precision":"year","title":"LAG-3 blockade","note":"First use in humans or first approval, as the technology record states it.","from":"lag3-blockade","refs":[]},{"group":"technology","date":"2022","precision":"year","title":"Parsortix label-free circulating tumour cell harvest","note":"First use in humans or first approval, as the technology record states it.","from":"parsortix-ctc-harvest","refs":[]},{"group":"technology","date":"2022","precision":"year","title":"Virus-specific T cells","note":"First use in humans or first approval, as the technology record states it.","from":"virus-specific-t-cells","refs":[]},{"group":"trial","date":"2022","precision":"year","title":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy reported","from":"nct02717611","refs":["cll","cll-relapsed","acalabrutinib"]},{"group":"trial","date":"2022","precision":"year","title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma reported","from":"nct04325828","refs":["salivary-gland","salivary-duct-carcinoma","apalutamide"]},{"group":"trial","date":"2022","precision":"year","title":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) reported","from":"nct03459846","refs":["urothelial","muscle-invasive-bladder-cancer","durvalumab","olaparib"]},{"group":"trial","date":"2022","precision":"year","title":"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma reported","from":"nct02963493","refs":["multiple-myeloma","melflufen","dexamethasone"]},{"group":"trial","date":"2022","precision":"year","title":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide reported","from":"nct03151811","refs":["multiple-myeloma","melflufen","pomalidomide","dexamethasone"]},{"group":"trial","date":"2022","precision":"year","title":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma reported","from":"nct03635983","refs":["melanoma","bempegaldesleukin","nivolumab"]},{"group":"trial","date":"2022","precision":"year","title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a reported","from":"nct04280081","refs":["thyroid","medullary-thyroid-cancer","selpercatinib"]},{"group":"trial","date":"2022","precision":"year","title":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate reported","from":"nct01517802","refs":["prostate","abiraterone","prednisone"]},{"group":"trial","date":"2022","precision":"year","title":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With...","from":"nct02677922","refs":["aml","aml-idh","azacitidine"]},{"group":"trial","date":"2022","precision":"year","title":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease reported","from":"nct02663908","refs":["prostate","degarelix"]},{"group":"trial","date":"2022","precision":"year","title":"AALL1231 reported","note":"Bortezomib did not significantly improve four-year event-free survival for the whole group (83.8 against 80.1 percent) but did for T-lymphoblastic lymphoma; cranial radiotherapy wa...","from":"aall1231","refs":["all-paediatric-high-risk","all-leukemia","leukaemia","bortezomib"]},{"group":"trial","date":"2022","precision":"year","title":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leu...","from":"nct02029443","refs":["cll","richter-transformation-cll","acalabrutinib"]},{"group":"trial","date":"2022","precision":"year","title":"AENEAS reported","note":"PFS 19.3 vs 9.9 months, HR 0.46.","from":"aeneas","refs":["nsclc","aumolertinib","gefitinib"]},{"group":"trial","date":"2022","precision":"year","title":"AGILE reported","note":"OS 24.0 vs 7.9 months; HR 0.44.","from":"agile","refs":["aml","aml-idh","ivosidenib","azacitidine"]},{"group":"trial","date":"2022","precision":"year","title":"AHOD1331 reported","note":"Three-year event-free survival 92.1 percent with brentuximab vedotin plus AVEPC against 82.5 percent with ABVE-PC (hazard ratio 0.41, p < 0.001), with no increase in toxicity; appr...","from":"ahod1331","refs":["hodgkin-lymphoma","advanced-stage-classical-hodgkin-lymphoma","childhood-cancers","brentuximab-vedotin"]},{"group":"trial","date":"2022","precision":"year","title":"Alliance A021501 reported","note":"18-month overall survival 66.7 percent with neoadjuvant modified FOLFIRINOX alone against 47.3 percent with chemotherapy plus hypofractionated radiotherapy; the radiotherapy arm cl...","from":"alliance-a021501","refs":["pancreatic","borderline-resectable-pdac","folfirinox","folfox"]},{"group":"trial","date":"2022","precision":"year","title":"ALPINE reported","note":"PFS HR 0.65; AF 5.2% vs 13.3%.","from":"alpine","refs":["cll","cll-relapsed","zanubrutinib","ibrutinib"]},{"group":"trial","date":"2022","precision":"year","title":"ANCHOR reported","note":"Progression to anal cancer 173 per 100,000 person-years with treatment against 402 with active monitoring, a 57 percent reduction (95% CI 6 to 80, p 0.03); the trial stopped early...","from":"anchor","refs":["anal-hsil-precursor","anal","fluorouracil","imiquimod"]},{"group":"trial","date":"2022","precision":"year","title":"Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma reported","note":"PFS 4.3 vs 4.5 months, HR 1.22; primary endpoint not met.","from":"anetumab-vs-vinorelbine-mpm","refs":["mesothelioma","anetumab-ravtansine","vinorelbine"]},{"group":"trial","date":"2022","precision":"year","title":"ARASENS reported","note":"OS HR 0.68.","from":"arasens","refs":["prostate","prostate-mhspc","darolutamide","docetaxel"]},{"group":"trial","date":"2022","precision":"year","title":"ASTRUM-005 reported","note":"OS 15.4 vs 10.9 months, HR 0.63.","from":"astrum-005","refs":["sclc","extensive-stage-sclc","serplulimab","platinum-etoposide"]},{"group":"trial","date":"2022","precision":"year","title":"ATHENA-MONO / GOG-3020 reported","note":"PFS 20.2 vs 9.2 months (HR 0.52).","from":"athena-mono","refs":["ovarian","platinum-sensitive-ovarian-cancer","rucaparib"]},{"group":"trial","date":"2022","precision":"year","title":"BRE12-158 (Hoosier Oncology Group) reported","note":"2-year DFS 56.6% (genomically directed) vs 62.4% (physician's choice); no difference in DFS, DDFS or OS. Post-surgical ctDNA predicted outcome.","from":"bre12-158","refs":["tnbc","tnbc-early","capecitabine"]},{"group":"trial","date":"2022","precision":"year","title":"CAPItello-291 reported","note":"PFS HR 0.60 overall; HR 0.50 in AKT-pathway-altered.","from":"capitello-291","refs":["breast-hr-positive","hr-positive-metastatic-post-cdk46","capivasertib"]},{"group":"trial","date":"2022","precision":"year","title":"CAPSTONE-1 reported","note":"OS 15.3 vs 12.8 months, HR 0.72.","from":"capstone-1","refs":["sclc","adebrelimab","carboplatin","etoposide"]},{"group":"trial","date":"2022","precision":"year","title":"CheckMate 548 reported","note":"OS 28.9 vs 32.1 months, HR 1.1 (95% CI 0.9-1.3); no PFS or OS benefit.","from":"checkmate-548","refs":["glioblastoma","nivolumab","temozolomide"]},{"group":"trial","date":"2022","precision":"year","title":"CheckMate 816 reported","note":"EFS HR 0.63; OS HR 0.72.","from":"checkmate-816","refs":["nsclc","resectable-nsclc","nivolumab"]},{"group":"trial","date":"2022","precision":"year","title":"CheckMate 915 reported","note":"Nivolumab plus low-dose ipilimumab did not improve recurrence-free survival over nivolumab alone after resection of stage III to IV melanoma.","from":"checkmate-915","refs":["stage-iii-melanoma","melanoma","nivolumab","ipilimumab"]},{"group":"trial","date":"2022","precision":"year","title":"CHRONOS reported","note":"Objective response 30 percent (8 of 27) and disease control 63 percent in ctDNA-selected patients; 31 percent of those screened were excluded by a resistance mutation.","from":"chronos","refs":["colorectal","panitumumab"]},{"group":"trial","date":"2022","precision":"year","title":"CodeBreaK 200 reported","note":"PFS HR 0.66; OS HR 1.01.","from":"codebreak-200","refs":["nsclc","kras-g12c-nsclc","sotorasib"]},{"group":"trial","date":"2022","precision":"year","title":"COSMIC-313 reported","note":"PFS HR 0.73; OS HR 1.02 (no benefit).","from":"cosmic-313","refs":["rcc","cabozantinib","nivolumab","ipilimumab"]},{"group":"trial","date":"2022","precision":"year","title":"DeFi reported","note":"PFS HR 0.29; ORR 41% vs 8%.","from":"defi","refs":["sarcoma","nirogacestat"]},{"group":"trial","date":"2022","precision":"year","title":"DESTINY-Breast04 reported","note":"OS HR 0.64.","from":"destiny-breast04","refs":["breast-hr-positive","tnbc","her2-low-metastatic-breast-cancer","tnbc-metastatic"]},{"group":"trial","date":"2022","precision":"year","title":"DESTINY-Lung01 reported","note":"High response rate with durable responses in HER2-mutant non-small-cell lung cancer; accelerated approval in August 2022.","from":"destiny-lung01","refs":["her2-mutant-nsclc","nsclc","lung-cancer","trastuzumab-deruxtecan"]},{"group":"trial","date":"2022","precision":"year","title":"DETERMINATION reported","note":"Early autologous transplant added to RVd and lenalidomide maintenance prolonged progression-free survival; overall survival did not differ at the primary analysis.","from":"determination","refs":["myeloma-transplant-eligible","multiple-myeloma","lenalidomide","bortezomib"]},{"group":"trial","date":"2022","precision":"year","title":"DYNAMIC reported","note":"Chemotherapy use 15% vs 28% with non-inferior RFS.","from":"dynamic","refs":["colorectal"]},{"group":"trial","date":"2022","precision":"year","title":"ECOG-ACRIN E3311 reported","note":"Two-year progression-free survival 96.9% (observation), 94.9% (50 Gy), 96.0% (60 Gy) and 90.7% (high-risk chemoradiation).","from":"ecog-e3311","refs":["oropharyngeal-cancer","hpv-positive-oropharyngeal-cancer","cisplatin"]},{"group":"trial","date":"2022","precision":"year","title":"EPCORE NHL-1 reported","note":"ORR 63%, CR 39%.","from":"epcore-nhl-1","refs":["dlbcl","epcoritamab"]},{"group":"trial","date":"2022","precision":"year","title":"ESTIMABL2 reported","note":"3-year event-free 95.6% vs 95.9% (non-inferior).","from":"estimabl2","refs":["thyroid"]},{"group":"trial","date":"2022","precision":"year","title":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Myc...","from":"nct02448381","refs":["cutaneous-t-cell-lymphoma","hypericin-sgx301"]},{"group":"trial","date":"2022","precision":"year","title":"FOENIX-CCA2 reported","note":"ORR 42%; PFS 9.0 months; OS 21.7 months.","from":"foenix-cca2","refs":["cholangiocarcinoma","intrahepatic-cholangiocarcinoma","futibatinib"]},{"group":"trial","date":"2022","precision":"year","title":"FURLONG reported","note":"PFS 20.8 vs 11.1 months, HR 0.44.","from":"furlong","refs":["nsclc","furmonertinib","gefitinib"]},{"group":"trial","date":"2022","precision":"year","title":"GEMSTONE-301 reported","note":"Median progression-free survival 9.0 against 5.8 months by blinded independent review, including after sequential chemoradiotherapy.","from":"gemstone-301","refs":["stage-iii-unresectable-nsclc","sugemalimab"]},{"group":"trial","date":"2022","precision":"year","title":"GEMSTONE-302 reported","note":"PFS 7.8 vs 4.9 months, HR 0.50.","from":"gemstone-302","refs":["nsclc","sugemalimab"]},{"group":"trial","date":"2022","precision":"year","title":"GÖTEBORG-2 (MRI-based prostate cancer screening) reported","note":"Clinically insignificant cancer 0.6% vs 1.2% (RR 0.46); clinically significant cancer 0.9% vs 1.1%.","from":"goteborg-2","refs":["prostate"]},{"group":"trial","date":"2022","precision":"year","title":"HIMALAYA reported","note":"OS HR 0.78; 5-year OS 19.6% vs 9.4%.","from":"himalaya","refs":["hcc","hcc-advanced","durvalumab","tremelimumab"]},{"group":"trial","date":"2022","precision":"year","title":"IMbassador250 reported","note":"Overall survival not improved: stratified hazard ratio 1.12 (95 percent confidence interval 0.91 to 1.37, p=0.28) for atezolizumab with enzalutamide against enzalutamide alone.","from":"imbassador250","refs":["prostate","prostate-mcrpc","atezolizumab","enzalutamide"]},{"group":"trial","date":"2022","precision":"year","title":"JCOG0802 / WJOG4607L reported","note":"Segmentectomy was superior to lobectomy for overall survival; in the pure-solid subgroup five-year overall survival was 92.4 against 86.1 percent (hazard ratio 0.64).","from":"jcog0802","refs":["resectable-nsclc","lung-adenocarcinoma"]},{"group":"trial","date":"2022","precision":"year","title":"JUPITER-06 reported","note":"OS 17.0 vs 11.0 months (HR 0.58); PFS HR 0.58.","from":"jupiter-06","refs":["esophageal","toripalimab","paclitaxel","cisplatin"]},{"group":"trial","date":"2022","precision":"year","title":"KEN SHE (single-dose HPV vaccine) reported","note":"Single-dose efficacy 97.5% against persistent HPV16/18.","from":"ken-she","refs":["cervical","head-and-neck","gardasil-9"]},{"group":"trial","date":"2022","precision":"year","title":"KEYNOTE-091 (PEARLS) reported","note":"Disease-free survival significantly improved in the overall population; the co-primary endpoint in the PD-L1 50 percent or greater population was not met.","from":"keynote-091","refs":["resectable-nsclc","pembrolizumab"]},{"group":"trial","date":"2022","precision":"year","title":"KEYNOTE-412 reported","note":"Pembrolizumab added to chemoradiotherapy did not significantly improve event-free survival.","from":"keynote-412","refs":["hpv-negative-head-and-neck-cancer","head-and-neck","pembrolizumab","cisplatin"]},{"group":"trial","date":"2022","precision":"year","title":"LEAP-002 reported","note":"OS HR 0.84, not significant.","from":"leap-002","refs":["hcc","lenvatinib","pembrolizumab"]},{"group":"trial","date":"2022","precision":"year","title":"LMS-04 reported","note":"Median PFS 12.2 vs 6.2 months (HR 0.41); overall survival also favoured the combination at later follow-up.","from":"lms-04","refs":["leiomyosarcoma","uterine-sarcoma","extremity-soft-tissue-sarcoma","retroperitoneal-sarcoma"]},{"group":"trial","date":"2022","precision":"year","title":"Lung-MAP S1800A: ramucirumab plus pembrolizumab reported","note":"Median overall survival 14.5 months with ramucirumab plus pembrolizumab versus 11.6 months with standard of care (hazard ratio 0.69); confirmation sought in the phase 3 Pragmatica-...","from":"lung-map-s1800a","refs":["nsclc","pdl1-high-nsclc","ramucirumab","pembrolizumab"]},{"group":"trial","date":"2022","precision":"year","title":"MAGNITUDE reported","note":"BRCA cohort rPFS HR 0.53; HRR-negative futility.","from":"magnitude","refs":["prostate","prostate-mcrpc","niraparib","abiraterone"]},{"group":"trial","date":"2022","precision":"year","title":"MajesTEC-1 reported","note":"ORR 63%, ≥CR 39%.","from":"majestec-1","refs":["multiple-myeloma","myeloma-relapsed-refractory","teclistamab"]},{"group":"trial","date":"2022","precision":"year","title":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer reported","from":"nct02492711","refs":["breast-cancer","margetuximab","trastuzumab"]},{"group":"trial","date":"2022","precision":"year","title":"MonumenTAL-1 reported","note":"ORR ~73%.","from":"monumental-1","refs":["multiple-myeloma","myeloma-relapsed-refractory","talquetamab"]},{"group":"trial","date":"2022","precision":"year","title":"MOUNTAINEER reported","note":"Phase 2 ORR 38.1%, DOR 12.4 months; phase 3 ongoing.","from":"mountaineer","refs":["colorectal","her2-amplified-colorectal","tucatinib","trastuzumab"]},{"group":"trial","date":"2022","precision":"year","title":"NCI-COG Pediatric MATCH (APEC1621) reported","note":"Actionable alteration in 31.5% of the first 1,000 tumours; 28.4% assigned and 13.1% enrolled on a treatment arm.","from":"pediatric-match","refs":["larotrectinib","selpercatinib","vemurafenib","erdafitinib"]},{"group":"trial","date":"2022","precision":"year","title":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma reported","note":"Pathological complete response in 40 of 79 patients (51 per cent, 95 per cent confidence interval 39 to 62) and pathological major response in a further 13 per cent, with grade 3 o...","from":"neoadjuvant-cemiplimab-cscc","refs":["cutaneous-scc","advanced-cutaneous-scc","skin-cancer","cemiplimab"]},{"group":"trial","date":"2022","precision":"year","title":"NeoTRIP (NeoTRIPaPDL1) reported","note":"pCR 48.6% vs 44.4% (OR 1.18, p 0.48), not significant; EFS (primary) awaited.","from":"neotrip","refs":["tnbc","tnbc-early","atezolizumab","carboplatin"]},{"group":"trial","date":"2022","precision":"year","title":"NICHE-2 reported","note":"pCR 68%, major pathologic response 95%; 3-year DFS 100%.","from":"niche-2","refs":["colorectal","msi-high-colorectal","nivolumab","ipilimumab"]},{"group":"trial","date":"2022","precision":"year","title":"NordICC (Nordic-European Initiative on Colorectal Cancer) reported","note":"10-year colorectal cancer risk 0.98% vs 1.20% (RR 0.82) by invitation; mortality RR 0.90, not significant.","from":"nordicc","refs":["colorectal"]},{"group":"trial","date":"2022","precision":"year","title":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study reported","from":"nct03381274","refs":["nsclc","oleclumab","osimertinib"]},{"group":"trial","date":"2022","precision":"year","title":"OPRA reported","note":"3-year disease-free survival 76% in both arms; 3-year survival without total mesorectal excision 41% (induction) vs 53% (consolidation).","from":"opra","refs":["colorectal","rectal-cancer","folfox","capox"]},{"group":"trial","date":"2022","precision":"year","title":"PARADIGM reported","note":"OS 37.9 vs 34.3 months (HR 0.82) in left-sided RAS wild-type disease.","from":"paradigm","refs":["colorectal","panitumumab","bevacizumab","folfox"]},{"group":"trial","date":"2022","precision":"year","title":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma reported","from":"nct02263508","refs":["melanoma","talimogene-laherparepvec","pembrolizumab"]},{"group":"trial","date":"2022","precision":"year","title":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chro...","from":"nct03268954","refs":["leukaemia","azacitidine","pevonedistat"]},{"group":"trial","date":"2022","precision":"year","title":"PREOPANC-1 reported","note":"5-year OS 20.5% vs 6.5% (HR 0.73, p 0.025); primary analysis median OS 16.0 vs 14.3 months (HR 0.78, p 0.096).","from":"preopanc","refs":["pancreatic","resectable-pdac","borderline-resectable-pdac","gemcitabine"]},{"group":"trial","date":"2022","precision":"year","title":"PROpel reported","note":"rPFS HR 0.66 (ITT); OS HR 0.81 (NS).","from":"propel","refs":["prostate","prostate-mcrpc","olaparib","abiraterone"]},{"group":"trial","date":"2022","precision":"year","title":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Trea...","note":"Five-year freedom from progression after prostatectomy 70.9 percent with prostate bed radiotherapy alone, 81.3 percent with added short-term androgen deprivation and 87.4 percent w...","from":"nct00567580","refs":["prostate","prostate-bcr","flutamide","bicalutamide"]},{"group":"trial","date":"2022","precision":"year","title":"QuANTUM-First reported","note":"OS 31.9 vs 15.1 months; HR 0.776.","from":"quantum-first","refs":["aml","aml-flt3","quizartinib","cytarabine-7-3"]},{"group":"trial","date":"2022","precision":"year","title":"QUILT 3.032 reported","note":"CR 71%.","from":"quilt-3-032","refs":["urothelial","nogapendekin-alfa","bcg-intravesical"]},{"group":"trial","date":"2022","precision":"year","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer reported","from":"nct00936390","refs":["prostate","bicalutamide","flutamide","goserelin"]},{"group":"trial","date":"2022","precision":"year","title":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy reported","from":"nct00769379","refs":["ductal-carcinoma-in-situ","trastuzumab","trastuzumab-biosimilars"]},{"group":"trial","date":"2022","precision":"year","title":"RATIONALE-302 reported","note":"OS 8.6 vs 6.3 months, HR 0.70.","from":"rationale-302","refs":["esophageal","tislelizumab"]},{"group":"trial","date":"2022","precision":"year","title":"RATIONALE-306 reported","note":"OS 17.2 vs 10.6 months (HR 0.66); PD-L1 ≥1% OS 16.8 vs 9.6 months.","from":"rationale-306","refs":["esophageal","tislelizumab"]},{"group":"trial","date":"2022","precision":"year","title":"RELATIVITY-047 reported","note":"PFS HR 0.75; median OS 51.0 vs 34.1 months.","from":"relativity-047","refs":["melanoma","advanced-melanoma","relatlimab-nivolumab","nivolumab"]},{"group":"trial","date":"2022","precision":"year","title":"SEQUOIA reported","note":"PFS HR 0.42 vs BR; 5-year PFS 72.2% in del(17p).","from":"sequoia","refs":["cll","cll-treatment-naive","pancreatic","metastatic-pdac"]},{"group":"trial","date":"2022","precision":"year","title":"SORAYA reported","note":"Objective responses in about a third of patients with folate receptor alpha-high platinum-resistant ovarian cancer; accelerated approval in November 2022.","from":"soraya","refs":["platinum-resistant-ovarian-cancer","high-grade-serous-ovarian-cancer","ovarian","mirvetuximab-soravtansine"]},{"group":"trial","date":"2022","precision":"year","title":"STELLAR (rectal cancer) reported","note":"Three-year disease-free survival 64.5 against 62.3 percent, non-inferior; more acute toxicity before surgery.","from":"stellar-rectal","refs":["colorectal","rectal-cancer","capox","capecitabine"]},{"group":"trial","date":"2022","precision":"year","title":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS reported","from":"nct02730299","refs":["all-leukemia","leukaemia","omidubicel"]},{"group":"trial","date":"2022","precision":"year","title":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) reported","from":"nct02477696","refs":["cll","cll-relapsed","acalabrutinib","ibrutinib"]},{"group":"trial","date":"2022","precision":"year","title":"Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma reported","from":"nct01127451","refs":["melanoma","advanced-melanoma","denileukin-diftitox"]},{"group":"trial","date":"2022","precision":"year","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). reported","note":"Durvalumab with chemotherapy improved progression-free survival (5.5 against 4.8 months, hazard ratio 0.74, p=0.0009) but not significantly overall survival; adding a limited cours...","from":"nct03164616","refs":["nsclc","sclc","durvalumab","tremelimumab"]},{"group":"trial","date":"2022","precision":"year","title":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) reported","from":"nct02542293","refs":["nsclc","durvalumab","tremelimumab","carboplatin"]},{"group":"trial","date":"2022","precision":"year","title":"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer reported","from":"nct02659514","refs":["breast-cancer","poziotinib"]},{"group":"trial","date":"2022","precision":"year","title":"SWOG S1801 reported","note":"2-year EFS 72% vs 49%; HR 0.58.","from":"swog-s1801","refs":["melanoma","stage-iii-melanoma","pembrolizumab"]},{"group":"trial","date":"2022","precision":"year","title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma reported","from":"nct01700946","refs":["all-leukemia","dexamethasone","vincristine","rituximab"]},{"group":"trial","date":"2022","precision":"year","title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. reported","from":"nct03330847","refs":["tnbc","tnbc-metastatic","olaparib","ceralasertib"]},{"group":"trial","date":"2022","precision":"year","title":"TOPAZ-1 reported","note":"OS HR 0.76; 2-year OS 23.6% vs 11.5%.","from":"topaz-1","refs":["cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma","gallbladder"]},{"group":"trial","date":"2022","precision":"year","title":"TRANSFORM reported","note":"EFS HR 0.36; CR 74% vs 43%.","from":"transform","refs":["dlbcl"]},{"group":"trial","date":"2022","precision":"year","title":"TreeTopp reported","note":"ORR 9.4% vs 4.8%; PFS 2.83 vs 2.79 months, HR 0.90; OS 7.8 vs 7.5 months, HR 1.11; gallbladder subgroup PFS 2.9 vs 1.6 months, HR 0.55 (0.26 to 1.19).","from":"treetopp","refs":["gallbladder","cholangiocarcinoma","biliary-tract-cancer","varlitinib"]},{"group":"trial","date":"2022","precision":"year","title":"TROPiCS-02 reported","note":"OS 14.4 vs 11.2 months, HR 0.79.","from":"tropics-02","refs":["breast-hr-positive","hr-positive-metastatic-post-cdk46","sacituzumab-govitecan"]},{"group":"trial","date":"2022","precision":"year","title":"TUXEDO-1 reported","note":"Intracranial responses in most patients with active HER2-positive breast cancer brain metastases.","from":"tuxedo-1","refs":["her2-positive-breast-brain-metastases","breast-her2-positive","breast-cancer","trastuzumab-deruxtecan"]},{"group":"trial","date":"2022","precision":"year","title":"VIOLET reported","note":"Physical function at five weeks 4.65 points better after keyhole surgery; serious adverse events after discharge 30.7 against 37.8 percent; no difference in progression-free or ove...","from":"violet","refs":["nsclc","lung-cancer","resectable-nsclc"]},{"group":"regulatory","date":"2022-01","precision":"month","title":"Satricabtagene autoleucel: designation (US)","note":"RMAT designation, CLDN18.2+ gastric cancer","from":"satricabtagene-autoleucel","refs":[]},{"group":"regulatory","date":"2022-01","precision":"month","title":"Telisotuzumab vedotin: designation (US)","note":"Breakthrough Therapy designation, c-MET overexpressing NSCLC","from":"telisotuzumab-vedotin","refs":[]},{"group":"regulatory","date":"2022-01-25","precision":"day","title":"Tebentafusp: approval (US)","note":"HLA-A*02:01+ unresectable or metastatic uveal melanoma: first TCR therapeutic approved","from":"tebentafusp","refs":[]},{"group":"regulatory","date":"2022-02-28","precision":"day","title":"Ciltacabtagene autoleucel: approval (US)","note":"Relapsed/refractory myeloma after ≥4 lines (CARTITUDE-1)","from":"ciltacabtagene-autoleucel","refs":[]},{"group":"guideline","date":"2022-03","precision":"month","title":"ESMO ESMO CPG bladder cancer 2022 (Powles et al.) for Bladder & urothelial cancer","note":"2 rows added. Anchored to Annals of Oncology publication, 2022.","from":"urothelial","refs":["avelumab","javelin-bladder-100","nivolumab","checkmate-274"]},{"group":"guideline","date":"2022-03","precision":"month","title":"NCCN 2021-2022 updates for Melanoma","note":"2 rows added. Anchored to FDA approvals of adjuvant pembrolizumab for stage IIB-IIC (December 2021, KEYNOTE-716) and nivolumab plus relatlimab (March 2022, RELATIVITY-047).","from":"melanoma","refs":["pembrolizumab","keynote-716","relatlimab-nivolumab","relativity-047"]},{"group":"regulatory","date":"2022-03","precision":"month","title":"Lenalidomide: label change (US)","note":"First generics launch (volume-limited)","from":"lenalidomide","refs":[]},{"group":"regulatory","date":"2022-03","precision":"month","title":"Sintilimab: complete response letter (US)","note":"Complete response letter for ORIENT-11 (first-line non-squamous NSCLC); ODAC voted 14 to 1 that additional data were needed for US applicability","from":"sintilimab","refs":[]},{"group":"regulatory","date":"2022-03-04","precision":"day","title":"Nivolumab: approval (US)","note":"Neoadjuvant NSCLC with chemotherapy (CheckMate 816)","from":"nivolumab","refs":[]},{"group":"regulatory","date":"2022-03-11","precision":"day","title":"Olaparib: approval (US)","note":"Adjuvant gBRCA high-risk HER2-negative early breast cancer (OlympiA)","from":"olaparib","refs":[]},{"group":"regulatory","date":"2022-03-18","precision":"day","title":"Relatlimab + nivolumab: approval (US)","note":"Unresectable or metastatic melanoma, age ≥12 (RELATIVITY-047): first LAG-3 therapy","from":"relatlimab-nivolumab","refs":[]},{"group":"regulatory","date":"2022-03-23","precision":"day","title":"Lutetium-177 vipivotide tetraxetan: approval (US)","note":"PSMA+ mCRPC after ARPI and taxane (VISION)","from":"pluvicto","refs":[]},{"group":"regulatory","date":"2022-04","precision":"month","title":"Paclitaxel / nab-paclitaxel: approval (US)","note":"First nab-paclitaxel generics","from":"paclitaxel","refs":[]},{"group":"regulatory","date":"2022-04","precision":"month","title":"Tebentafusp: approval (EU)","note":"EMA approval","from":"tebentafusp","refs":[]},{"group":"expected","date":"2022-04-01","precision":"day","title":"Lung-MAP (SWOG S1400 and S1900): primary completion","note":"Actual primary completion date on ClinicalTrials.gov.","from":"lung-map","refs":[]},{"group":"regulatory","date":"2022-04-01","precision":"day","title":"Axicabtagene ciloleucel: approval (US)","note":"Second-line LBCL refractory or relapsed within 12 months (ZUMA-7)","from":"axicabtagene-ciloleucel","refs":[]},{"group":"guideline","date":"2022-05","precision":"month","title":"NCCN 2022 update for HER2-positive breast cancer","note":"1 row recategorised. Anchored to FDA approval of trastuzumab deruxtecan in the second line, May 2022 (DESTINY-Breast03).","from":"breast-her2-positive","refs":["trastuzumab-deruxtecan","trastuzumab-emtansine","destiny-breast03"]},{"group":"regulatory","date":"2022-05","precision":"month","title":"Ripretinib: label change (US)","note":"Label updated with INTRIGUE data","from":"ripretinib","refs":[]},{"group":"regulatory","date":"2022-05","precision":"month","title":"Sacituzumab tirumotecan: filing (China)","note":"Merck licenses ex-Greater-China rights (deal expanded December 2022)","from":"sacituzumab-tirumotecan","refs":[]},{"group":"regulatory","date":"2022-05-04","precision":"day","title":"Trastuzumab deruxtecan: approval (US)","note":"Second-line HER2+ metastatic breast cancer (DESTINY-Breast03)","from":"trastuzumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2022-05-25","precision":"day","title":"Ivosidenib: approval (US)","note":"Combination with azacitidine (AGILE)","from":"ivosidenib","refs":[]},{"group":"guideline","date":"2022-06","precision":"month","title":"NCCN 2022 update for Diffuse large B-cell lymphoma","note":"1 row recategorised. Anchored to FDA approvals of axicabtagene ciloleucel (April 2022, ZUMA-7) and lisocabtagene maraleucel (June 2022, TRANSFORM) in the second line.","from":"dlbcl","refs":["axicabtagene-ciloleucel","lisocabtagene-maraleucel","zuma-7","transform"]},{"group":"regulatory","date":"2022-06","precision":"month","title":"Rucaparib: label change (US)","note":"Later-line treatment indication withdrawn after ARIEL4 OS imbalance","from":"rucaparib","refs":[]},{"group":"regulatory","date":"2022-06-29","precision":"day","title":"Cadonilimab: approval (China)","note":"First PD-1×CTLA-4 bispecific approved anywhere","from":"cadonilimab","refs":[]},{"group":"guideline","date":"2022-08","precision":"month","title":"NCCN 2022 updates for Prostate cancer","note":"2 rows added. Anchored to FDA approvals of 177Lu-PSMA-617 (March 2022, VISION) and darolutamide with docetaxel (August 2022, ARASENS).","from":"prostate","refs":["pluvicto","vision","darolutamide","abiraterone"]},{"group":"guideline","date":"2022-08","precision":"month","title":"NCCN 2022 updates for Triple-negative breast cancer (TNBC)","note":"2 rows added. Anchored to FDA approvals of adjuvant olaparib for germline BRCA carriers (March 2022, OlympiA) and trastuzumab deruxtecan for HER2-low disease (August 2022, DESTINY-...","from":"tnbc","refs":["olaparib","olympia","trastuzumab-deruxtecan","destiny-breast04"]},{"group":"regulatory","date":"2022-08-03","precision":"day","title":"Acalabrutinib: label change (US)","note":"Tablet formulation co-administrable with acid-reducing agents","from":"acalabrutinib","refs":[]},{"group":"regulatory","date":"2022-08-05","precision":"day","title":"Trastuzumab deruxtecan: approval (US)","note":"HER2-low metastatic breast cancer (DESTINY-Breast04); first HER2-low indication","from":"trastuzumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2022-08-11","precision":"day","title":"Trastuzumab deruxtecan: approval (US)","note":"HER2-mutant NSCLC (accelerated)","from":"trastuzumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2022-08-24","precision":"day","title":"Teclistamab: approval (EU)","note":"Conditional approval: first BCMA bispecific worldwide","from":"teclistamab","refs":[]},{"group":"regulatory","date":"2022-09","precision":"month","title":"Relatlimab + nivolumab: approval (EU)","note":"EMA approval, PD-L1 <1% melanoma","from":"relatlimab-nivolumab","refs":[]},{"group":"regulatory","date":"2022-09-02","precision":"day","title":"Durvalumab: approval (US)","note":"Biliary tract cancer with chemotherapy (TOPAZ-1)","from":"durvalumab","refs":[]},{"group":"regulatory","date":"2022-09-21","precision":"day","title":"Selpercatinib: approval (US)","note":"RET-fusion solid tumours (tumour-agnostic, accelerated); full approval in NSCLC","from":"selpercatinib","refs":[]},{"group":"guideline","date":"2022-10","precision":"month","title":"ESMO ESMO CPG gastric cancer 2022 (Lordick et al.) for Gastric & gastro-oesophageal junction cancer","note":"2 rows added. Anchored to Annals of Oncology publication, 2022.","from":"gastric","refs":["nivolumab","checkmate-649","pembrolizumab","trastuzumab"]},{"group":"regulatory","date":"2022-10-21","precision":"day","title":"Durvalumab: approval (US)","note":"HCC with tremelimumab (HIMALAYA)","from":"durvalumab","refs":[]},{"group":"regulatory","date":"2022-10-25","precision":"day","title":"Teclistamab: approval (US)","note":"Accelerated approval, relapsed/refractory myeloma after ≥4 lines (MajesTEC-1)","from":"teclistamab","refs":[]},{"group":"guideline","date":"2022-11","precision":"month","title":"NCCN 2022 updates for Ovarian cancer","note":"1 row removed, 1 row added. Anchored to Sponsor withdrawals of later-line PARP inhibitor treatment indications (June to September 2022) after overall-survival signals; FDA accelera...","from":"ovarian","refs":["olaparib","rucaparib","niraparib","mirvetuximab-soravtansine"]},{"group":"regulatory","date":"2022-11","precision":"month","title":"Niraparib: label change (US)","note":"Second-line maintenance restricted to gBRCA after OS data","from":"niraparib","refs":[]},{"group":"regulatory","date":"2022-11","precision":"month","title":"Tarlatamab: designation (US)","note":"Breakthrough Therapy designation, ES-SCLC after platinum","from":"tarlatamab","refs":[]},{"group":"regulatory","date":"2022-11-10","precision":"day","title":"Brentuximab vedotin: approval (US)","note":"Paediatric high-risk Hodgkin lymphoma","from":"brentuximab-vedotin","refs":[]},{"group":"regulatory","date":"2022-11-14","precision":"day","title":"Mirvetuximab soravtansine: approval (US)","note":"Accelerated approval, FRα-high platinum-resistant ovarian cancer (SORAYA)","from":"mirvetuximab-soravtansine","refs":[]},{"group":"regulatory","date":"2022-11-22","precision":"day","title":"Belantamab mafodotin: withdrawal (US)","note":"Withdrawn after DREAMM-3 failed to confirm benefit","from":"belantamab-mafodotin","refs":[]},{"group":"regulatory","date":"2022-12","precision":"month","title":"Loncastuximab tesirine: approval (EU)","note":"Conditional marketing authorisation","from":"zynlonta","refs":[]},{"group":"regulatory","date":"2022-12","precision":"month","title":"Lutetium-177 vipivotide tetraxetan: approval (EU)","note":"EMA approval","from":"pluvicto","refs":[]},{"group":"regulatory","date":"2022-12","precision":"month","title":"Nonavalent HPV vaccine: label change (WHO)","note":"One-dose schedule endorsed (SAGE)","from":"gardasil-9","refs":[]},{"group":"regulatory","date":"2022-12","precision":"month","title":"Revumenib: designation (US)","note":"Breakthrough Therapy designation","from":"revumenib","refs":[]},{"group":"regulatory","date":"2022-12-01","precision":"day","title":"Olutasidenib: approval (US)","note":"Study 2102-HEM-101 pivotal cohort","from":"olutasidenib","refs":[]},{"group":"regulatory","date":"2022-12-11","precision":"day","title":"Rucaparib: withdrawal (US)","note":"Clovis Oncology bankruptcy; asset sold to pharma&","from":"rucaparib","refs":[]},{"group":"regulatory","date":"2022-12-12","precision":"day","title":"Adagrasib: approval (US)","note":"Accelerated approval, KRAS G12C NSCLC after ≥1 therapy","from":"adagrasib","refs":[]}]},"route":"/years/2022/","neighbours":{"year":[{"id":"2021","kind":"year","name":"2021 in oncology","route":"/years/2021/"},{"id":"2023","kind":"year","name":"2023 in oncology","route":"/years/2023/"}]}}